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INTRODUCTION 
Diabetes mellitus is a collection of common metabolic disorder mainly 
considered by hyperglycaemia which results commencing from defective 
insulin secretion or insulin action or together.1 It is a diverse group of diseases 
with different group of etiology such as social, environmental and genetic 
factors which acting concurrently or mutually. 2 
 Insulin is a hormone which controls the body metabolism of 
carbohydrates, proteins and lipids at different level. Chronic poor glycemic 
control will cause disorder like dyslipidemia, hypo thyroidism, cardiac disease, 
central nerve system problems and also poor control of infections.3 
 In India, Type 2 Diabetes mellitus is an epidemic disorder due to social 
influence and changes in life style. As per WHO estimation, the universal 
prevalence of Diabetes mellitus was 170 million (2.8%) in 2002, this number 
expected to grow up to 366 million (4.4%) or more in 2030. 4- 6 
 Thyroid hormones play an indispensable role in various metabolic 
process in our body. The thyroid gland produce two type of hormones, T3   and 
T4.7 The major variation in the thyroid hormones system are a decrease in the 
Thyroid stimulating hormone (TSH) stimulation over the thyroid gland, which 
possibly caused by central hypothyroidism and in the local production of T3 
and  T4.8,9 These hormones play a important role in cell differentiation during 
development and also help to maintain thermo genesis and metabolic 
homeostasis in the adults.10, 11 
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  In addition, they have a crucial role in maintaining cellular homeostasis; 
when Thyroid hormones levels in the body are out of balance, they can cause 
multiple disorders, which include diabetes mellitus, cardiovascular disease, and 
chronic liver disease.12, 13 
 Thyroid diseases in Diabetes mellitus patients are regularly encountered. 
The clinical relationships between them are more commonly recognized with 
hypothyroidism among Diabetes patients. Thyroid hormones are insulin 
antagonists.Iodothyronines with high levels act as diabetogenics while low 
levels of iodothyronines inhibits the development of Diabetes.14, 15   
Diabetes and thyroid disease are the generally two common and 
important endocrine disorders seen within adults population. Excess or 
deficiency of either insulin or thyroid hormones can result in functional 
abnormalities of one another, as both of them are closely involved in cellular 
metabolism. 16
 
 Glycemic control is influenced by Thyroid hormones through a range of 
actions on intermediary metabolism.  Hyperglycaemia is promoted by Excess 
thyroid hormones levels through facilitating glucose intestinal absorption, 
enhancing glycogenolysis and Gluconeogenesis, and increasing insulin 
clearance.17,18 In diabetes patients, hypothyroidism may control the glucose 
metabolism by various levels. These effects consist of decreases in hepatic 
glucose production, Gluconeogenesis and increased peripheral glucose 
consumption. The general effects of these processes are a progress to 
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hypoglycaemia. Recurrent hypoglycaemic attacks were recognized in children 
and adolescents who have diabetes and subclinical hypothyroidism.19, 20 
A numerous studies were reported the occurrence of thyroid disease in 
diabetes patients changing from 2.2% to 17 %. 21, 22 However few studies shows 
even higher up to 46.5% 21, 23. The relationship between type 1 DM and thyroid 
dysfunctions are proved one and may be an autoimmune process. 24 But in 
India, inadequate data is available on thyroid diseases in type 2 diabetes 
patients. So our study designed to evaluate incidence of thyroid dysfunction 
among type 2 diabetes mellitus subjects residing in south Indian region. 
 With these background, the present study aims to focus on to find out 
the prevalence of thyroid dysfunction in  Type 2 DM population. An effort was 
made to compare and correlate these two metabolic disorders by taking into 
consideration of various biochemical parameters.   
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AIM: 
Our research focused on to investigate the relationship between diabetes 
mellitus and thyroid profile status in Type 2 Diabetes mellitus patients.    
           
OBJECTIVES 
1. To study the correlation between Diabetes mellitus and Thyroid 
dysfunction by estimating F T3, F T4 and TSH in type 2 diabetic subjects. 
2. To estimate the thyroid hormones level in Type2 Diabetes mellitus. 
3. To study the relationship between various parameters like lipid profile, 
renal profile in various status of thyroid dysfunction in Diabetic mellitus 
patients. 
4. To determine the prevalence and degree of various Thyroid dysfunction 
between type 2 diabetes mellitus patients. 
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REVIEW OF LITERATURE 
 DIABETES MELLITUS: 
Diabetes is a major health problem in the world. It produces serious 
health - related and socioeconomic impact on individual person and also on 
populations. In addition, the pandemic increase of diabetes is spurred on by 
transitioning demographic like Population aging, socioeconomic, nutritional 
and Lifestyle patterns and migratory cause and a joined proliferation in 
overweight and obese adults and  in children. 25, 26 
Diabetes is a common endocrine metabolic disorder. It is characterized 
by increased glucose level from a multiple interaction of hereditary and 
environmental factors due to decreased insulin secretions or resistance or 
both.27 
HISTORY:  
Polyuric diseases have been described for over 3500 years. The Hindu 
physicians, Charak and Sushrut, who wrote between 400 and 500 bc were 
probably the first to recognize the sweetness of diabetic urine .The word 
“diabetes” came from the Greek word meant for a syphon; and the sweet taste 
of diabetic urine was documented at beginning of the first millennium, but the 
adjective “mellitus ” (honeyed) was further  added by Rollo in the late 18th 
century., British physiologist Matthew Dobson was the first person, who 
showed in his Experiments   that the sweet-tasting substance in the urine of 
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diabetic patients was sugar in 1776. The British Army surgeon John Rollo 
(1749–1809), further added the term “mellitus” (Greek word- meant for honey) 
to “diabetes” to differentiate it from diabetes insipidus. 25, 27  
PREVALENCE: 
Diabetes is a major health problem affecting large population worldwide 
.WHO projected that the total figure of people among DM has risen from 108 
million in 1980 to 422 million in 2014. The general predominance of DM in 
adults above 18 yrs of age was since 4.7% in 1980 which increased to 8.5% in 
2014.  It increases with age and approximately half of the cases are occur in 
people older than 55 years. 28, 74 
As per the International Diabetic Federation (IDF) 2015 ,  INDIA is one 
of the 6 main countries of the IDF SOUTH EAST ASIA (SEA) region.415 
million people have diabetes in the globe and 78 million people in the SEA 
region. By 2040 this will get higher to 140 million in SEA region. In India, 
there were 69.1 million cases of DM in 2015 with prevalence of 8.7% of adult 
population (20-79 years). Most of the diabetics live in underdeveloped and 
developing countries (up to 80%). 29 
The prevalence of Type 2 DM is increasing rapidly due to reduced 
activity because of more industrialization.30, 31 Many factors such as dietary 
habits, sedentary life style, ethnicity, obesity and hypertension and genetic 
predisposition to the disease are the major causes to this epidemic. 
[32].Uncontrolled DM is the major cause of micro and macro vascular 
complications like blindness, kidney failure, heart attacks, stroke, and lower 
  
 
FIGURE 1 
WORLDWIDE PREVALENCE OF DIABETES MELITUS(30) 
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limb amputation. Because of these long term complications, there are increased 
mortality and morbidity among diabetic subjects. As per WHO in 2012, 1.5 
million deaths were directly due to DM and another 2.2 million deaths were 
related to high blood glucose.33 
In absolute numbers, India will continue to be the country with the most 
individuals living with diabetes, projected in 2030 to have nearly 80 million 
people with diabetes.34 The greatest increases in diabetes prevalence will be in 
India. Diabetes is the common heterogeneous endocrine disorder rising up to 
approximately 20% in urban and 10% in rural population. 35 
 
CLASSIFICATION OF DIABETES MELLITUS: 
DM is classified based on the pathogenesis of hyperglycemia. The 
American diabetes association (ADA) classified DM as type 1 DM , Type 2 
DM and other specific types of diabetic whi,ch include MODY , 
Endocrinopathies, IGT & IFG and GDM others.36  
Type 2 DM: 
PATHOGENESIS: 
The Type-2 diabetes is accounts for just about 90% of all cases of 
diabetes. It is a heterogeneous, complex, interrelated disease involving multiple 
etiologies.37 It is characterized through a combination of both insulin resistance 
and progressive beta cell worsening leads to altered insulin secretion and 
release, increased hepatic glucose synthesis as the outcome of increased 
glycogenolysis and gluconeogenesis .38 There are two major specific 
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pathological deficiency reported in patients with type 2 DM one is decreased 
biological action of insulin  on peripheral tissues, this is insulin resistance. The 
other one is beta cell dysfunction, which is lack of ability of the pancreas to 
turn out sufficient insulin to compensate insulin resistance. 39 
T2DM patients presenting with a few symptoms and not prone for 
ketosis because they are independent on insulin to avoid ketonuria. Obesity is 
more commonly associated with this type and weight reduction alone usually 
improves hyperglycaemia in these patients. Most people acquire this disease 
after the 40 years of age but it may also develop in younger people. Type2 DM 
in children and adolescent is an emerging, significant health problem. 40 
The overall pathological features of type 2 diabetes include increased 
absorption of intestinal glucose, reduced insulin secretion and obvious changes 
in the beta cells mass which include insulin degradation and enhanced 
catecholamine.41 
THYRIOD H0RMONES: 
Thyroid hormone plays an important role in various metabolic processes 
like carbohydrate, lipid metabolism and pancreatic functions. Alteration of 
thyroid hormone levels directly affects the basal metabolic rate. 42 
PREVALENCE: 
The prevalence of the thyroid disease in general population has a great 
variability varying from 6.6% to 13.4%.43, 44 This difference may be due to 
difference in diagnostic criteria of thyroid disease, degree of iodine intake 
among various regions, difference in sensitivities of the TSH assays and the 
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large population diversity.45 Thyroid dysfunction is more common in female 
than male and this may be due to inhibition of disease activity by androgens 
and also exacerbation by estrogens.46 
 
THYROID GLAND ANATOMY AND PHYSIOLOGY: 
The thyroid is the largest endocrine gland, weighing approximately 20 
gm. It is butterfly shaped and placed over the front of the neck. 47 The thyroid 
gland has two important  physiological endocrine systems. Among this, the 1st 
system, which has most of the thyroid, is accountable for the making of the 
thyroid hormones triiodothyronine (T3) and thyroxine (T4). The 2nd endocrine 
cell system is responsible for the production of the peptide hormone Calcitonin. 
Thyroid hormones secretion is controlled by Thyroid stimulating hormone 
(TSH) from the anterior pituitary gland which is upregulated by thyrotropin 
regulating hormone (TRH) from hypothalamus. There is a fine control of 
hypothalamus- pituitary-Thyroid axis. 47   
 
FUNCTION OF THYROID: 
 Thyroid hormones has influence on numerous body systems which 
include growth & development, muscular function, cardiovascular system, 
sympathetic nervous system, and carbohydrate metabolism.48 
Thyroid hormones are important for maturation and differentiation during 
development. They have metabolic functions to control the basic metabolic 
  
 
FIGURE 2 
 
HOMEOSTASIS IN THE HYPOTHALAMUS-PITUITARY - THYROID AXIS(84) 
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rate. It influences the metabolic pathways and it has either catabolic or anabolic 
action.49 
There are 2 main mode of action in the body: 1. Increase in the overall 
metabolism 2. Promote growth of children. Some of the mechanisms of actions 
of thyroid hormones are  
 1. Increase protein synthesis 2. Increase the amount and activity of 
enzyme the system 3. Increase the volume and number of mitochondria      
4. Their effect on the active transport of ions.50, 51. 
The common thyroid problems involve abnormal production of thyroid 
hormones either increased production which leads to hyperthyroidism or 
insufficient production leads to hypothyroidism. 
The causes for the above said statement is due to dysfunction of 52 
1. Thyroid hormone synthesis 
2. Thyroid hormone transport and metabolism 
3. TSH action 
4. Thyroid Hormone binding protein. 
THYRIOD AND DIABETES:   
Both diabetes and Thyroid diseases are common endocrinopathies. 
There is a deep relationship between them. Thyroid hormones affect the 
carbohydrate metabolism and pancreatic function. At the same time, diabetes 
affects the thyroid function to a large extent. Thyroid dysfunction is much 
common in diabetic population compared to non-diabetic population. The 
relationship between DM and thyroid disorder is a complex interdependent 
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interaction. 53 This relationship was first investigated by coller and huggins in 
1927.they proved the worsening of DM in hyperthyroidism. 56 
Prevalence of thyroid dysfunction is higher in diabetics than in normal 
population, estimation varying from 2.2% to 15 % 67 in DM compared to 6% in 
non DM population. Nevertheless, many studies have found out even higher 
prevalence of thyroid disease in diabetics, which was 31% and 46.5% 
respectively. 54, 23, 14 
The case control study by Vinu Vji et al, found the prevalence of thyroid 
disease among type2 DM was to be 28.75%. Udiong et al study   found a 
higher incidence of   abnormal thyroid hormone levels up to(46.5%)  among 
diabetics in Nigeria ( Hypothyroidism was 26% and hyperthyroidism 
was19.9%). Gurjeet Singh et al  conducted study in Punjabi population 
comprising of  80 DM and 80 controls, found that 30% of patients had 
abnormal thyroid hormone levels and the TSH level was significantly higher.  
EFFECTS OF THYROID HORMONES OVER DM: 
Thyroid hormones are insulin antagonists, because of both insulin 
resistance and beta cell dysfunction are inversely related to thyroid stimulating 
hormone. 55 Whenever TSH increased, thyroid hormones were decreased and 
also antagonistic role of insulin are weakened.57 Both are involved in cellular 
metabolism, excess and deficit of any one can result in functional derangement 
of the other.21 
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Thyroid hormones have direct control on insulin secretion. Both hyper 
and hypothyroidism, have a direct relation to insulin resistance.58 There is a 
reduction of insulin secretions by the beta cells. In hyperthyroidism glucose 
induced insulin secretion is reduced and increased in hypothyroidism.and it has 
increased susceptibility to hypoglycemia, that’s why complicating DM 
management. It also influences a diversity of abnormalities in blood lipid 
metabolism which include increased serum triglyceride, low-density 
lipoprotein (LDL) and total cholesterol concentration59. Subclinical 
hypothyroidism can also exacerbate the coexisting dyslipidemia which is 
frequently found in type 2diabetes and further increase the possibility of 
cardiovascular diseases. Sufficient thyroid hormone replacement therapy will 
repeal the lipid abnormalities.60, 83 
The relationship between cholesterol and TSH was customized via 
insulin resistance. So, elevated serum TSH level and comparative insulin 
resistance are the furthermost risk for the development of increased 
dyslipidemia.65 
Palma et al concluded the necessary for screening of DM patients for 
thyroid disease to reduce the possibility of aggravation of common risk factors 
like hypertension and dyslipidemia. 
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RELATIONSHIP BETWEEN THYROID DISORDER AND GLYCEMIC 
STATUS 69 
Thyroid dysfunction in DM  mainly depends on glycaemic status which 
is mainly modulated by TRH and TSH level. It is also influenced by the 
occurrence of thyroid hormone binding inhibitor (THBI) which decreased the 
extra thyroidal conversion of T4 to T3. 70, 71  
In hyperthyroidism, the response of beta cells to glucose or 
catecholamine is increased due to increased beta cell mass. The liver 
endogenous glucose production is elevated and hepatic insulin sensitivity is 
reduced due to glycogenesis and glycogenolysis. Due to increased lipolysis in 
hyperthyroidism, there is an increase in FFA levels which stimulate hepatic 
gluconeogenesis. FFA increase also due to catecholamine stimulatied lipolysis 
by excess thyroid hormone level.73In the muscles there is an increase in skeletal 
muscle glucose utilization which is mediated by insulin stimulated glucose 
oxidation rate. 61 
The clinical diagnosis of thyroid disease in DM patients is difficult. 
Because poor DM control symptoms are similar with hyperthyroidism (weight 
loss, increased appetite and fatigue) and also severe DM nephropathy may be 
mistaken for hypothyroidism (edema, weight gain, and pallor).62, 63 
  
  
 
 
FIGURE 3 
 
RELATIONSHIP BETWEEN INSULIN RESISTENCE 
AND THYROID DISORDERS: 75 
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EFFECTS OF DM OVER THYROID HORMONES:    
Diabetes mellitus control the thyroid function in two sites: one at the 
stage of hypothalamic control of TSH release and secondly at peripheral tissue 
level by converting T4 to T364. Hyperglycemia may cause reduction in hepatic 
conversion of T4- T3, decreased serum concentration of T3, and raised intensity 
of reverse T3.68 
There is an alteration of thyroid hormone level in diabetic patients with 
poor glycemic control. In DM patients, nocturnal TSH level is decreased and 
the response to TRH is impaired. Insulin resistance and beta cell functions 
inversely co-related to TSH, that’s may be by insulin antagonistic effects of 
thyroid hormone along with an increase in TSH. The higher serum TSH usually 
corresponds to lower thyroid hormones via negative feedback mechanism.72 
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MATERIALS AND METHODS 
STUDY DESIGN      : Case control study 
PLACE OF STUDY   :   CMCH&RC, Irungalur, Trichy. 
PERIOD OF STUDY :  JANUARY 2015- JUNE 2016                                     
SAMPLE SIZE             :  170Cases and 50 Controls. 
(Cases- Type 2 Diabetes mellitus patients)   (Controls – non-diabetic patients) 
 AGE                             :     30-80 years  
 SEX                               :     Both females (n=97) and males (n=123). 
 GEOGRAPHICAL DISTRIBUTION:  Both urban and rural areas.  
 
ETHICAL CONSIDERATIONS: 
       The necessary approval was obtained to conduct the study from the   
Chennai medical college hospital and research centre, ethical committee, 
Irungalur, Trichy. Patients were given an explanation regarding the intention of 
the study and informed written consent was obtained, confidentiality about 
their results was assured. Their participation was optional. 
 
SELECTION OF CASES AND CONTROLS: 
     170 Type 2 Diabetic patients   and 50 non diabetic patients between the  age  
group  of 30-80  years who  were all attending  in  medicine, surgery and 
Endocrinology department OPD at CMCH&RC, TRichy , were  selected  for  
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the study. All the patients were included as cases evaluated and diagnosed as 
Type 2 Diabetes mellitus on the basis of history and Biochemical 
investigations. 
Inclusion Criteria:   
• 170 Patients with Type2 Diabetes mellitus (age groups 30-80 years)  
and 50   non diabetic were also included as controls   
Exclusion Criteria:  
• Seriously ill patients  
• Adults who are previously diagnosed as cases of Type 1 diabetes 
mellitus     
• Specific types of Diabetes Mellitus                    
• Gestational Diabetes mellitus.(GDM) 
• Known case of thyroid disease. 
• Cancer patients.  
 
STUDY PROTOCOL: 
 After obtaining the informed consent, all patients were subjected to detailed   
history taking and clinical examination. 
History: 
      A detailed history of duration and severity of the disease, clinical symptoms 
, and also family history, personal history and drug history and  Co-morbid 
diseases was also obtained . 
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CLINICAL EXAMINATION:  
A thorough physical examination was done to look for local and 
systemic features. 
 
ANTHROPOMETRIC MEASUREMENTS: 
Measurement of weight, height, and blood pressure were done. 
The Body Mass Index was determined by wt and height calculations 
using the following equation:  
                     BMI = Weight in Kg / Square of height in meters.    
According to Indian guidelines, a BMI - 23 to 24.9 is defined as 
overweight, a BMI-  ≥  25 is moderate obesity and a BMI  ≥  30 is severe 
obesity. 
The blood pressure was taken in the sitting posture and the average of 
two measurements was recorded in right arm. 
 
COLLECTION OF SPECIMENS: 
5ml of fasting venous blood samples were collected in clot activator 
coated polypropylene tubes by venupuncture under strict aseptic precaution as 
soon as the subjects got admitted as per the inclusion criteria.Similar way 2 
hours post prandial also collected. Blood samples were centrifuged at 3500 rpm 
used for 10 minutes and serum was separated. 8-12 hours fasting samples, 2 
hours post prandial samples were collected from all subjects during their 
hospital visit and analysis of below said parameters were done 
18 
 
INVESTIGATIONS: 
 Fasting   and Post prandial blood glucose, and HbA1c 
 Renal parameters (serum urea, creatinine) 
 Fasting Serum Lipid parameters which include (Total cholesterol,     
           Triglycerides, LDL-cholesterol, HDL- cholesterol) 
           Above mentioned test were analyzed in BS-420 Fully auto analyzer 
 Serum Thyroid profile - FT3 , FT4 and TSH was done in ELISA reader. 
 
SAMPLE STORAGE: 
The specimens were freezed at -20°C for storage until analysis for 
thyroid profile. 
 
ESTIMATION OF FASTING AND POST PRANDIAL BLOOD 
GLUCOSE: 85 
METHODOLOGY:   Glucose Oxidase peroxidise method (END POINT) 
PRINCIPLE: 
The serum /plasma Glucose was first oxidized (GOD) to gluconic acid 
with the release of hydrogen peroxide by the enzyme glucose oxidase, which is 
further transformed to water and nascent oxygen by the action of enzyme 
peroxidase (POD). 4- Aminoantipyrine is an oxygen acceptor takes up the 
oxygen and simultaneously with phenol forms a pink colored   chromogen 
which is measured at 505 nm. 
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Glucose + o2 + H2O              GOD                      Gluconic acid + H2O2 
H2O2   + phenol + 4-Aminoantipyrine           POD            (Red) quinoneimine       
                                                                                             complex        + H2O 
GLUCOSE REAGENTS: 
Phosphate buffer (Ph 7.5)       : 0.1 mol/L 
4-Aminoantipyrine                  : 5.0 mmol/L 
Peroxidase                               :  >1.5 KU/L 
Glucose Oxidase                    : >15 KU/L 
Phenol                                   :  5.0 mmol/L 
Glucose Standard (concentration: 100 mg /dl) 
 
PROCEDURE: 
 Take 3 test tubes and labelled them as Blank (B), Std. (S) and (T) as follows: 
                   
 Incubation period  10min & Reaction temperature  37◦C. 
Mix up well and read absorbance of Std. (S) and Test (T) alongside Blank 
(B) on 505 nanometer or through green filter (500- 540 nm). 
CALCULATION: 
                                 Glucose conc (mg/dl) =      ∆ Abs for Test    ×    100 
                                                                             ∆ Abs for Standard 
S.NO REAGENT BLANK STANDARD TEST 
1. GLUCOSE  REAGENT 1.0 ml 1.0 ml 1.0 ml 
2. GLUCOSE STANDARD _ 10 µl _ 
3. SPECIMEN _ _ 10 µl 
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    Reference value: 
       Serum / Plasma (fasting) Glucose      : 70- 100 mg/dl 
       Serum / Plasma (post prandial)      : < 140 mg/dl 
 
 
ESTIMATION OF HbA1c:89 
METHODOLOGY:   
PARTICLE ENHANCED IMMUNO TURBIDIMETRIC TEST 
PRINCIPLE: 
 
Total Hemoglobin and HbA1c in haemolysed blood is combining with 
the equal affinity to particle in R1. The amount of binding is proportional to the 
comparative concentrations of the both substances in the blood. 
Mouse antihuman HbA1c monoclonal antibody (R2) binds to particle bound 
HbA1c.Goat antimouse IgG polyclonal antibody (R3) is interact with R2 also 
agglutination takes place. The calculated absorbance be proportional to the 
HbA1c bound to particles, which consecutively proportional to the % of 
HbA1c in the sample. 
 
REAGENTS: 
R1:Buffer  : 20m mol/L                Latex   : 0.14% 
R2: Buffer: 10mmmol/L & Mouse antihuman HbA1c monoclonal  
Antibody: 5.5 mg/dL 
R3: Buffer : 10mmol/L   &    Goat antimouse IgG polyclonal  
Antibody: 67mg/dL. 
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ASSAY PROCEDURE:  
Wavelength: 660nm   Optical path :1cm     Temperature: 31◦c 
 
  Sample                    20µL 
 Reagent1          750µL 
Mix and incubate for 2 min , then add  
Reagent 2                250µL 
Mix and incubate for 3 min , then add 
Reagent 3                 125 µL 
Mix - read absorbance after exactly 2 min    
 
CALCULATION  
The conc. of the HbA1c in unknown sample is derived from a calibration curve  
by appropriate mathematical models. 
LIMIT OF DECTECTION: 
Limit of detection is 10mmol/mol HbA1c 
REFERENCE RANGE:  
 HbA1c mmol/mol % 
Non -diabetic 20-42 4-6 
Target of treatment Less than 53 Less than 7 
Change of treatment Greater than 64 Greater than 8 
 
According to ADA      >6.5%   -     Diabetic  
                                  5.7-6.4% - Pre- Diabetic. 
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LIPID PROFILE 
ESTIMATION TOTAL CHOLESTEROL88     
METHODOLOGY:  Cholesterol oxidase / peroxidase 
PRINCIPLE: 
               Cholesterol esters are hydrolyzed to produce cholesterol. Then, free 
cholesterol takes part in two coupled reactions that permit to measure 
cholesterol photometrically. 
  
The reaction sequence is as follows: 
        Cholesterol esterase 
Cholesterol ester + H2O                                 Cholesterol + Fatty acid 
       Cho. Oxidase             
Cholesterol + ½ O2 + H2O                             Cholestenone   + H2O2 
                 POD 
2H2O2 + 4- Aminoantipyrine + Phenol               Quinoneimine  + 4H2O 
 
REAGENTS: 
Cholesterol Reagent: 
Mes buffer pH6.5   : 75 mmol/L 
Phenol     : 6mmol/L 
3,5 Dichlorophenol    : 0.2mmol/L 
4 amino antipyrine   : 0.5 mmol/L 
Cholesterol esterase   ≥ 500KU/L 
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Cholesterol oxidase    ≥ 300 KU/L 
Peroxidise     ≥ 1200 KU/L 
Standard (5ml):          Cholesterol 200mg/dl 
  The reagents were stored at 2ºC-8ºC. 
PREPARATION OF WORKING SOLUTION: 
           The reagents are allowed to attain room temperature.  Both the reagent 
and the std. are supplied for instant use. 
PROCEDURE:  
Reagent / Test Blank Standard Test 
Distilled water    10µL     --  
 Reagent 1mL   1mL  1ml 
Standard  --   10µL  -- 
Sample  --    -- 10µL 
 
Mixed and incubated for 10 min at 370C and read it by 505 nanometer. 
CALCULATIONS: 
Sample absorbance       × 200 = Sample concentration (mg/dl)      
Standard absorbance 
 
 LINEARITY:  This method is linear up to 1000mg/dl. 
REFERENCE VALUES: 
        Serum Cholesterol (Total) 
            Desirable value              :  up to 200 mg/dl 
            Borderline High             :  200 - 239 mg/dl 
            High   value                   :   > 240 mg/dl. 
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QUANTITATIVE ESTIMATION OF SERUM TRIGLYCERIDES86     
METHODOLOGY: Glycerol-3- phosphate oxidase (GPO) 
PRINCIPLE: 
Quantification of triglycerides by enzymatic separation with lipoprotein  lipase. 
Quinoneimine which is separated from 4-aminoantipyrine and 4-Chlorophenol 
by hydrogen peroxide  of peroxidase act as indicator. 
The reaction sequence is as follows: 
              LPL 
     Triglycerides                                 Glycerol + Fatty acid     
                                         GK 
     Glycerol + ATP                             Glycerol -3-phosphate + ADP 
               GPO    
     Glycerol -3-phosphate    + oxygen                     Dihydroxyacetone phosphate + H2O2     
                       POD       
     2H2O2 + Aminoantipyrine + 4- Chlorophenol                Quinoeimine + HCl+ H2O                    
 
REAGENTS: 
four-chlorophenol                         :  4 mmol / L 
ATP                                          :  2 mmol / L 
Mg2+                                 : 15mmol/L 
Glycerolkinase                                    :  ≥0.4 kU/L 
Lipoprotein lipase                               :  ≥ 2 kU/L 
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Peroxidase                                          : ≥ 2 kU/L 
4-Aminoantipyrine                             : 0.5mmol/l 
Glycerol -3- phosphate – oxidase     : ≥0.5 kU /L 
Good’s buffer at pH  7.2                    :50 mmol / l 
Standard:  Triglycerides 200mg/dl 
  The reagents were stored at 2ºC-8ºC 
PREPARATION OF WORKING SOLUTION: 
The reagents are allowed to attain room temperature.  Both the reagent and the 
std. are supplied for ready to utilize. 
PROCEDURE: 
Reagent / Test Blank Standard Test 
Distilled water 10µl  --  -- 
Reagent 1ml 1ml  1ml 
Standard -- 10µl  -- 
Sample -- -- 10µl 
  
It was gently mixed, incubated the tubes for ten minutes by room temperature 
and measured by 505 nanometre. 
CALCULATIONS: 
Sample absorbance     × 200 = Sample concentration (mg/dl)                    
Standard absorbance 
 
To correct for free glycerol, subtract 10mg/dl from the triglycerides value 
calculated above. 
LINEARITY:   2-1000mg/dl. 
REFERENCE VALUES: 
            Desirable  value             : < 150 mg/dl 
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ESTIMATION OF SERUM LOW DENSITY LIPOPROTEIN 
CHOLESTEROL86 (LDL-c) 
METHODOLOGY: 
                       Direct enzymatic method 
PRINCIPLE: 
                  In the first step, LDL is secluded when non-LDL-lipoprotein is 
enzymatically processed. In the 2nd step, LDL is unconfined and LDL-
cholesterol is selectively determined by a enzymatic reaction which produce 
colour change. 
1. LDL + Reagent 1                          Protected LDL 
                        
                                                             CHE &CHO 
 Chylomicrons , HDL, VLDL                             Cholestenone  +  H2O2   
            
Catalase 
 H2O2                                    H2O     
2. Protected LDL +  Reagent 2                              LDL 
           CHE &CHO 
 LDL-C                                       Cholestenone + H2O2 
                
POD
 
 H2O2 + 4- Aminoantipyrine + H-DAOS                             Color   
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REAGENTS: 
Reagent 1: 
              Cholesterol esterase                                 :  ≥2.5 kU/L 
              Cholesterol oxidase                                 :  ≥2.5 kU/L 
              N-(2-hydroxy-3-sulfopropyl)-                  :   0.5mmol/L 
              3,5- Dimethoxyaniline, (H-DAOS) 
              Good’s buffer pH 6.8                                   :  20 mmol / L 
              Catalase                                                          : ≥500 kU/ 
Reagent 2: 
               Good’s buffer ( pH   7.0  )                        :25 mmol / L 
                Peroxidase                                               : ≥15 kU/L 
               4-Aminoantipyrine                                   : 3.4mmol/L 
  Calibrator: LDL- Cholesterol 132 mg/dL 
       The reagents were   stored at 2ºC-8ºC 
 
PREPARATION OF WORKING SOLUTION: 
           The reagents are allowed to attain room temperature. Both of the reagent 
and the std. are supplied as ready to use. 
PROCEDURE: 
       The sample and the working solution were brought to room temperature 
prior to use. 
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Reagent / Test BLANK CALIBRATOR TEST 
 CALIBRATOR        _       3.0µl   - 
SAMPLE        -         -       3.0µl 
DISTILLED 
WATER       3.0µl       _  
REAGENT 1      280µl     280µl     280µl 
Mix, incubate 5min,at  37◦C , read  absorbance (A1), then add:   
REAGENT 2     70 µl 70 µl 70 µl 
 
Mixed well and incubated up to 5 min, at 37◦C, read absorbance (A2) again 
Blank 
 ∆A = [(A2 - A1) sample or calibrator ] -   [(A2-A1)Blank] 
CALCULATIONS: 
∆A Sample          X  Conc.calib = Sample concentration(mg/dl)              
∆A calibrator  
 
LINEARITY:  This method is to determine LDL-C concentration within a 
measuring range from 1- 400mg/dl. 
 
REFERENCE VALUES: 
           Serum LDL-C: 
            Desirable value             : ≤ 130 mg/dl 
            Borderline High    : 130 - 160 mg/dl 
            High    value                  : above  160 mg/dl      
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HIGH DENSITY LIPOPROTEIN CHOLESTEROL86 (HDL-c) 
METHODOLOGY: Direct enzymatic method 
PRINCIPLE OF THE METHOD: 
           Antibodies beside the human lipoproteins are used to form antigen-
antibody complexes with VLDL, LDL and chylomicrons in a way that only 
HDL-cholesterol is determined by an enzymatic cholesterol measurement. 
The reaction sequence is as   follows: 
    Anti-human  β – lipoprotein antibodies 
LDL,VLDL,Chylomicrons                     Antigen – antibody    complexes +HDL                                                                                              
                      
HDL –C + H2O +O2    CHE &CHO      Cholest-4-en-3-one + Fatty acid + H2O2 
                                                                     
                   POD 
H2O2 + F- DAOS + 4- Aminoantipyrine                         Blue Complex +  H2O       
REAGENTS: 
Reagent 1: 
              Ascorbate oxidase                                  :   2250 U/ L 
              Anti-human β - lipoprotein 
              Antibody (sheep) 
               Peroxidase                                              : 2000 U/L 
               4-Aminoantipyrine                                 : 0.75mmol/l 
               Good’s buffer (pH 7.0)                           :  25 mmol / l 
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Reagent 2: 
               Good’s buffer (pH 7.0)                            :   30 mmol / l 
               Cholesterol esterase    enzyme                 : 4000 U/L 
               Cholesterol oxidase enzyme                   : 20000U/L 
               N-Ethyl N (2-hydroxy 3-sulfopropyl) -      :0.8mmol/L 
               3,5- dimethoxy-4-fluoroaniline, 
               Na. salt  
Calibrator:  HDL-Cholesterol     : 50.6 mg/dl 
 
PREPARATION OF WORKING SOLUTION: 
           The reagents were allowed to attain room temperature.  Both reagent and 
std. were supplied ready to use. 
PROCEDURE: 
       The sample and the working solution were brought to room temperature 
prior to use. 
Reagent / Test BLANK CALIBRATOR TEST 
 CALIBRATOR        _       2.4µl   - 
SAMPLE        -       - 2.4µl 
DISTILLED 
WATER       2.4µl       _  
REAGENT 1      240µl     240µl 240µl 
 Mix and incubate for 5min - 37◦C, take reading of absorbance 
(A1, afterwards add:   
REAGENT 2  60 
microlit 60 microlit 60 microlit 
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∆A = ( A2 - A1) sample or calibrator. 
It was mixed and incubated the test tubes for five minutes by room 
temperature. Take reading of the absorbance A2. 
 
CALCULATIONS: ∆A Sampl  X conc. Calib = Sample concentration (mg/dl)                                         
                      ∆ A Calibrator 
LINEARITY:  From 1-180 mg/dl. 
REFERENCE VALUES: 
        Serum HDL-C: Males     : 30-60 mg/dl 
                                   Females   : 35-75 mg/dl 
 
ESTIMATION OF UREA74  
PRINCIPLE: 
       Urea is hydrolysed by enzyme urease to give ammonia and CO2. This 
ammonia reacts with 2-oxoglutarate and NADH with glutamate-dehydrogenase 
(GLDH) enzyme to obtain glutamate & NAD+. The test is optimized so that 
GLDH is the rate limiting enzyme. The decrease in the absorbance is 
proportional to the urea concentration in the given time intervals. 
 
REAGENTS: 
ENZYMES: 
Tris buffer (pH7.8)             : 125 mmol/l 
ADP                                    : 0.88 mmol/l 
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Urease                                 : >20kU/l 
GLDH                                 : >0.3kU/l 
Sodium Azide                     : 0.095% 
 
SUBSTRATES: 
2-oxoglutrate                      : 25mmol/l 
NADH                                : 1.25mmol/l 
Sodium Azide                     : 0.095% 
 
STANDARD: 
Urea                                           80mg/dl or 13.3mmol/l Or 
Sodium Azide                             0.095% 
 
PREPARATION OF REAGENT: 
Reagent is prepared by mixing 4 parts of enzymes with 1 part of substrates. 
 
ASSAY: 
Wavelength:              340nm, 334nm, 365nm 
Optical path:             1cm 
Temperature:             25°C, 30°C to 37°C 
Measurement  :   Adjacent to reagent blank (RB). 1 reagent blank       
                       for each series is required. 
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PROCEDURE: 
REAGENT START PROCEDURE:       
 
 
 
 
 
 
 
 
 
SAMPLE START PROCEDURE:       
Reagent / Test Reagent 
blank(RB) 
Sample / standard  
Sample / 
standard 
- 10µl 
Working reagent  1000µl 1000µl 
Mix , read absorbance of  Sample /standard after 30 seconds(A1), 
start  timer simultaneously & read after exactly 1 
minute(A2).calculate the absorbance difference: 
∆A Sample /standard= (A2-A1)-∆ARB 
 
Reagent / Test Reagent Blank Standard 
Sample /standard - 10µL 
Enzyme  1000µL 1000 µL 
Mix, incubate for approx.1 minute. 
Substrate  250µL 250µL 
Mix , read absorbance of  Sample /standard after 30 
seconds(A1), start  timer simultaneously & read after exactly 1 
minute(A2).calculate the absorbance difference: 
∆A Sample /standard= (A2-A1)-∆ARB. 
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CALCULATION: 
                         C= 80.0× ∆A Sample/ ∆A standard [mg/dl]  or 
                         C=13.3× ∆A Sample/ ∆A standard [mmol/l] 
LINEARITY: The test is linear up to 300mg/dl or 50mmol/l. 
 
REFERENCE VALUES: 
SERUM UREA value: 15-45 mg/dl or 1.7 -8.3 mmol/l 
 
DETERMINATION OF SERUM CREATININE74 
METHOD : JAFFE’S KINETIC METHOD 
PRINCIPLE OF THE METHOD: 
Creatinine present in the sample combines with picric acid in presence of 
alkaline medium producing orange-red coloured complex - creatinine picrate. 
The difference in absorbance at predetermined time during conversion is 
proportional to the concentration of creatinine in the sample. 
Creatinine  +  Picric acid   →  Creatinine  picrate color complex 
REAGENTS: 
Reagent 1: NAOH                               : o.2 mol / L 
Reagent 2: Picric acid                          :  20 mmol/L 
Standard :    (Creatinine 2 mg/dL): 
                    Creatinine                           177µmol/L 
 
PROCEDURE: 
The sample and the working solution are brought to room temperature 
prior to use. 
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GENERAL SYSTEM PARAMETERS: 
Reaction Type                           :        Fixed Time 
Reaction slope                           :        Increasing 
Wavelength                               :        500 nm (490-510 nm) 
Flow cell Temp.                         :        20°C- 25°C or 37°C 
Path length                                 :        1 cm 
 
Substrate start 
Reagent / Test Blank  Sample or standard 
Sample or standard - 5oµL 
Dist.Water 5oµL - 
Reagent 1 1000µL 1000µL 
Mix and incubate 0-5 mins, then add, 
Reagent 2 250µL 250µL 
Mix and read absorbance A1 after 60 sec, read absorbance A2 after 
further 120 sec 
 
∆A=(A2-A1) sample or standard 
 
Sample start 
Reagent / Test Blank  Sample or standard 
Sample or standard - 5oµL 
Dist.Water 5oµL - 
Mono reagent 1000µL 1000µL 
Mix and read absorbance A1 after 60 sec, read absorbance A2 after 
further 120 sec 
 
∆A=(A2-A1) sample or standard 
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Calculation: 
Creatinine (mg/dL) = ∆A sample / ∆A (std/cal) × conc. Std/cal (mg/dL) 
Measurement range:  0.2 - 15 mg/dL. 
Limit of Detection: Above  0.2 mg/dL. 
 
REFERENCE VALUES: 
        Serum Creatinine: 
            Males         : 0.7-1.3 mg/dL 
            Females     : 0.6-1.1 mg/dL 
 
ESTIMATION OF THYROID PROFILE87 
ESTIMATION OF FT3 (FREE T3)87 
METHODOLOGY: Enzyme linked immunosorbent assay (ELISA) 
PRINCIPLE: 
    Principle of competitive binding of Free T3 in a test sample and T3 –
Peroxidase conjugate for a narrow number of binding sites present on the anti –
T3 ( Sheep) coated well. So the quantity of T3 –Peroxidase conjugate bound to 
the well is inversely proportional to the concentration of FT3 in the specimen. 
    After incubation, specimen and T3 –Peroxidase unbound enzyme conjugate 
is separated by washing in the equilibrium state. TMB /Substrate solution is 
mixed and a blue colour forms. The intensity of this colour, which changes to 
yellow after stopping the response is inversely proportional to the quantity of 
FT3 in the sample. 
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     The ELISA micro plate readers is used to determine the absorbance.  A dose 
response curve is used to extrapolate Specimen’s concentration by using serum 
calibrators of known antigen concentrations.   
KIT INSIDE: 
1. MICROTITER STRIPS 
           Eight - Well snap off strips, coated by  anti –T3 sheep antibiody) 
2. CALIBRATORS: ( 6 × 2 ml) instant use,  human serum 
     FT3  CONCNTRATION      Pg/ml 
       Calibrator  1     O (A) 
        Calibrator  2     1 (B ) 
         Calibrator  3     3 (C) 
        Calibrator  4    5 (D) 
         Calibrator  5    8 (E) 
         Calibrator  6    16 (F) 
 
3. ENZYME – ANTIGEN CONJUGATE: (13 ml) 
     Ready for use, coloured red T3 – HRP Conjugate in a protein stabilising 
matrix. -  1%. 
4. WASH SOLUTION : (20 ml) 
    Concentrated used for ca.1000ml . Tris buffer saline.  -   250 mmol/l 
5. SUBSTRATE REAGENT :(14ml)  
     3, 3’, 5,5’, tetramethylbenzidine           -   .5 g/l 
     Sodium acetate( buffer)                         -   .05mol/l 
     Urea hydrogen peroxide                        -  .03% 
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6. STOP SOLUTION :  ( 7.5ml) 
H2SO4                                                       - .5 mol/l 
PRESERVATIVES: Total concentration < .04%. 
SPECIMEN: 
• Serum  
• Specimens stored up to 5 days – ( 2-8◦C), for 30 days at -20◦C. 
PROCEDURE: 
            STEP 1            WELL (µl) 
    A1…..D2 
CALIBRATORS 
       E2 
   SPECIMEN 
    CAL –A-F;  in duplicate           50          _ 
 SPECIMENS, CONTROLS; in 
copy 
            _         50 
  CONJUGATE           100         100 
 
Gently shake and cover MIC with Adhesive strip 
Incubate for 60 min at 20….25◦C 
Wash up to 3 times  
                WASH          300    300 
          2 nd     STEP   
              SUBSTRATE          100     100 
Don’t vibrate MIC after SUB 
addition 
 
Incubate for 15 min at 20-25◦C   
             STOP          50    50 
  mix up cautiously  
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Read the absorbance immediately or within 30 mins by 450nm, via a 
reference wavelength of 630- 690nm. 
VALIDATION OF TEST: 
      The test results are accessible if calibration of highest absorbance CAL- A ≥ 1.3. 
CALCULATION: 
       In a lin –lin graph, Plot absorbance is calculated in opposition to 
calibrator. Suitable interpolations of plotted measuring points are 
produced in a calibration curve, from which the analyte concentration in 
the sample can be measured. 
REFERENCE VALUE: 
 
ADULT 
 pg /dl 
PREGNANT  
pg / dl 
MEAN 2.8 3.0 
STANDARD DEVIATION 
(S.D) 0.7 0.6 
EXPECTED RANGE (≥2 S.D ) 1.4-4.2 1.8-4.2 
                 
ESTIMATION OF FT4 (FREE T4)87 
METHODOLOGY : ENZYME LINKED IMMUNOSORBENT ASSAY.  
PRINCIPLE: 
The ELISA is based on the rule of competitive binding between FT4 in a test 
sample and T4 –Peroxidase conjugate for a narrow number of binding sites on 
the anti –T4( Sheep) coated well. Thus the quantity of binding is inversely 
proportional to the concentration of FT4 in the specimen. 
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Following incubation of specimen and T4 –Peroxidase conjugate unbound 
enzyme conjugate is separated in the equilibrium state by washing. TMB 
/Substrate solution is added and a blue colour forms. The intensity of the colour 
, which changes to yellow after stopping the reaction , is inversely proportional 
to the quantity of FT4 in the sample. 
ELISA micro plate reader used to read the absorbance of 630 nanaometer. The 
dose response curve developed by using serum calibrators of known antigen 
concentrations is used to extrapolate Specimen’s concentration. 
 KIT CONTENTS: 
7. MICROTITER STRIPS ( in 1n strip holder) 
           8 - Well snap –off strips, coated with anti –T4sheep) 
8. CALIBRATORS: ( 6 × 2 ml) for instant use, in human serum 
FT4 CONCNTRATION      ng/ml 
       Calibrator  1     0 ( A) 
        Calibrator  2     0.40 (B) 
         Calibrator  3     1.25 (C) 
        Calibrator  4    2.10 (D) 
         Calibrator  5    5.00 (E) 
         Calibrator  6    7.40 (F) 
 
9. ENZYME – ANTIGEN CONJUGATE: (13 ml)                               
Instant use coloured green T4-HRP Conjugate in a protein stabilising matrix.-
1%. 
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10. WASH SOLUTION : (20 ml) 
    Concentrated for ca.1000ml  
    Tris buffered saline.  -   250 mmol/l 
11. SUBSTRATE REAGENT :(14ml)  
     3, 3’, 5,5’, tetramethylbenzidine            –   0.5 g/l 
     Sodium acetate buffer                              -   0.05mol/l 
     Urea hydrogen peroxide                          -   0.03% 
12. STOP SOLUTION :  ( 7.5ml) 
    Sulphuric acid                                            -0.5 mol/l 
PRESERVATIVES: Total concentration < 0.04%. 
SPECIMEN: 
• Serum  
• Specimens stored up to 5 days at 2-8◦C, for 30 days at -20◦C. 
PROCEDURE:     
            STEP 1            WELL (µl) 
    A1…..D2 
CALIBRATORS 
       E2 
   SPECIMEN 
    CAL –A-F;  in duplicate           50          _ 
 SPECIMENS, CONTROLS; in 
duplicate 
            _         50 
  CONJUGATE           100         100 
 
shake gently and cover MIC with Adhesive strip, Incubate for 60 min at 
20….25◦C, Wash 3 times  
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                WASH          300    300 
               STEP -2  
              SUBSTRATE          100     100 
Do no rock MIC after SUB addition 
 
Incubate 15 min at 20…25◦C   
             STOP          50    50 
  Mix cautiously  
 
Note the absorbance at 450nm as soon as possible or within 30min, after 
terminating of reaction, using a reference wavelength of  630- 690nm. 
VALIDATION OF THE TEST: 
      The test results are accessible if calibration of highest absorbance  
CAL- A ≥ 1.3. 
CALCULATION: 
In a lin –lin graph, Plot absorbance is calculated in opposition to calibrator. 
Suitable interpolations of plotted measuring points are produced in a 
calibration curve, from which the analyte concentration in the sample can 
be measured. 
REFERENCE VALUE:  
 ADULT REGNANT 
MEAN 1.4  ng /ml 1.5 ng / ml 
STANDARD DEVIATION  (S.D) 0.3  ng /ml 0.37ng /ml 
EXPECTED RANGE (≥ 2 S.D ) 0.8-2.0 ng /ml 0.8-2.2 ng/ ml 
 
43 
 
ESTIMATION OF TSH87 
METHODOLOGY: ENZYME LINKED IMMUNOSORBENT ASSAY 
(ELISA) 
PRINCIPLE: 
          The ELISA is based on the principle of competitive binding between 
TSH in a test specimen and TSH –Peroxidase conjugate for a limited number of 
binding sites on the anti –TSH ( Sheep) coated well. Thus the amount of TSH –
Peroxidase conjugate bound to the well is inversely proportional to the 
concentration of TSH in the specimen. 
After incubation of sample and TSH –Peroxidase  unbound enzyme 
conjugate is removed in the stability state by washing. TMB /Substrate solution 
is mixed and a blue colour develops. The intensity of this colour  is inversely 
proportional to the quantity of TSH in the sample. 
ELISA micro plate readers or programmed ELISA systems (HUMAN’S 
Huma - Reader or ELISYS line) are used to read the absorbance.The dose 
response curve developed by using serum calibrators of known antigen 
concentrations is used to extrapolate Specimen’s concentration 
 
 KIT CONTENTS: 
1. MICROTITER STRIPS ( in 1n strip holder) 
Eight  Well snap –off strips , with anti –TSH sheep coating) 
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2. CALIBRATORS: ( 6 × 2 ml) all set for use,  human serum 
     TSH CONCNTRATION      mIU/ml 
Calibrator  1     0 ( A) 
Calibrator  2     0.5 (B) 
Calibrator  3     3.0 (C) 
Calibrator  4    6.0 (D) 
Calibrator  5    15.0 (E) 
 Calibrator  6       30.0 (F) 
 
3. ENZYME – ANTIGEN CONJUGATE: (13 ml) 
     For instant use, red anti-TSH (goat), HRP - labelled. 
4. WASH SOLUTION : (50 ml) 
    Concentrated for ca.1000ml – pH 6.25 ± 0.1 
    Tris buffered.  -  10mmol/l   
    NaCl                 - 8gm/l 
5. SUBSTRATE REAGENT :(13ml)  
     3, 3’, 5,5’, tetramethylbenzidine (TMB) –   1.2mmol/l 
      Hydrogen peroxide                                  -   ≤ 6.0 mmol/l 
STOP SOLUTION:  ( 15ml) 
    H2so4                                           -0.5 mol/l 
PRESERVATIVES: Total concentration < 0.1%. 
SPECIMEN: 
• Serum  
• Specimens stored up to 5 days at 2-8◦C, for 30 days at -20◦C. 
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PROCEDURE: 
Keep Reagents and specimens  at room temperature prior to use 
            STEP 1            WELL (µl) 
    A1…..D2 
CALIBRATORS 
       E2 
 SPECIMEN 
    CAL –A-F;  in copy           50          _ 
 SPECIMENS, CONTROLS; in 
copy 
            _         50 
  CONJUGATE           100         100 
 
shake gently and cover MIC with Adhesive strip, Incubate for 60 min at 20-
-.25◦C, Wash  up to 3 times  
                WASH          300    300 
               STEP -2  
              SUBSTRATE          100     100 
Don’t shake MIC after SUB addition  
Incubate for 15 min at 20…25◦C   
             STOP          100    100 
  Mix cautiously  
 
Note absorbance at 450nanometre  in 30min, after reaction at 630- 
690nanometre  
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 TEST VALIDATION : 
       If The following criteria are met, The test results are valid. 
  CALIBRATOR       ACCEPTED RANGE (OD) 
                   A       < .05 
                   B      >2.0 × absorbance CAL(A) 
                   C     >3.0 × absorbance CAL(B) 
                   D   >1.4 ×  absorbance CAL(C) 
                   E     >1.9 × absorbance CAL(D) 
                   F    >1.5 × absorbance CAL(E) 
                  F      >1.2 
 
CALCULATION: 
                In a lin –lin graph, Plot absorbance is calculated in opposition to 
calibrator. Suitable interpolations of plotted measuring points are produced 
in a calibration curve, from which the analyte concentration in the sample 
can be measured. 
REFERENCE VALUE: 
 NORMAL RANGE: 0.3 - 4.0 mIU/L                      
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STATISTICAL ANALYS:  
 All the data was initially entered to Microsoft Excel 2010 and later these 
spreadsheets were used for analysis. Statistical analysis was done by using 
SPSS version 20.0.  
 Descriptive statistics were calculated as frequency, percentage, mean 
and standard deviation. Descriptive data were represented using various 
tables, graphs, diagrams etc. 
  For all the statistical tests of significance, p value of <0.05 was 
considered to reject the null hypothesis.  
 After the normality tests (Kolmogorov-Smirnov and Shapiro-Wilk) 
showed normal distribution of continuous variables, Student “t” test was 
done to test the difference in means between the study group and the 
control group. 
 ANOVA test was done to test the difference in means between more 
than 2 groups. 
 For categorical nominal variables, Chi-square test was done to test the 
association between the variables. 
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RESULTS 
Table 1 Age distribution of the study population (n=220) 
Age group 
T2DM Cases 
N (%) 
Control  
N (%) 
Total 
N (%) 
31-40 years 31 (18.2) 8 (16) 39 (17.7) 
41-50 years 57 (33.5) 25 (50) 82 (37.3) 
51-60 years 50 (29.4) 10 (20) 60 (27.3) 
61-70 years 30 (17.6) 5 (10) 35 (15.9) 
71-80 years 2 (1.2) 2 (4) 4 (1.8) 
Total 170 (100) 50 (100) 220 (100) 
 
Chi-square p value: 0.121 
Mean age (± S.D): 50.65 (9.92) years, minimum: 32 years, maximum: 80 years. 
Comments: About 37% of the study subjects were in the age group of 41-50 
years while 27% were aged 51-60 years. The study group is not significantly 
different from control group in age distribution. 
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    Fig. 4. Bar chart showing gender distribution of the study population 
(n=220)  
 
 
 
Chi-square p value: 0.022 
Comments:  
Majority of the study subjects were males (56%) while the remaining 
44% were females. The control group had more males than the study group and 
this difference in gender distribution was statistically significant. 
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Table 2 Distribution of BMI across the groups (n=220) 
BMI group 
Group 
Total 
Case Control 
Underweight 
(<18.5) 
1 0 1 
0.6% 0% 0.5% 
Normal 
(18.5-22.9) 
37 19 56 
21.8% 38% 25.5% 
Overweight 
(23 - 24.9) 
35 9 44 
20.6% 18% 20.0% 
Obesity 
(≥ 25) 
97 22 119 
57.1% 44% 54.1% 
Total 
170 50 220 
100.0% 100.0% 100.0% 
 
Chi square p value: 0.130 
Comments:  
The differences in the distribution of overweight and obese individuals 
across the groups were not statistically significant. 
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Fig 5 Bar chart showing distribution of BMI across the groups (n=220) 
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Table 3 Distribution of blood glucose and glycated haemoglobin values 
between the T2DM group and control group (n=220) 
 Group N Mean Mean difference 
Student “t” 
test 
p value 
Fasting Blood 
Glucose (mg/dl) 
T2DM 170 156.45 
64.573 <0.001 
Control 50 91.88 
Post-prandial 
Blood Glucose 
(mg/dl) 
T2DM 170 246.98 
135.476 <0.001 
Control 50 111.50 
HbA1c (%) 
T2DM 170 7.094 
2.0441 <0.001 
Control 50 5.050 
 
Comments: 
Subjects in the study group had higher mean fasting and post-prandial blood 
glucose levels and HbA1clevels than controls as they are diabetics and this 
mean difference was statistically significant (p<0.05). 
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Table 4 Distribution of renal function tests between the T2DM group and 
control group (n=220) 
 Group N Mean 
Mean 
difference 
Student “t” 
test 
p value 
Blood Urea 
(mg/dl) 
T2DM 170 21.81 
0.866 0.402 
Control 50 20.94 
Serum 
creatinine 
(mg/dl) 
T2DM 170 0.905 
-0.0287 0.302 
Control 50 0.934 
 
Comments:  
Subjects in the study group had higher mean blood urea and serum 
creatinine levels than controls but this mean difference was not statistically 
significant (p>0.05). 
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Table 5 Distribution of total cholesterol levels between the T2DM group 
and control group (n=220) 
 Group N Mean Mean difference 
Student “t” 
test 
p value 
Total cholesterol 
(mg/dl) 
Study 170 187.64 
5.855 0.342 
Control 50 181.78 
 
Comments: 
Subjects in the study group had higher mean total cholesterol levels than 
controls but this mean difference was not statistically significant (p>0.05). 
 
Table 6 Distribution of serum triglyceride levels between the T2DM group 
and control group (n=220) 
 Group N Mean Mean difference 
Student “t” 
test 
p value 
Serum 
triglycerides 
(mg/dl) 
Study 170 144.81 
27.552 0.003 
Control 50 117.26 
 
Comments:  
Subjects in the study group had higher mean serum triglyceride levels 
than controls and this mean difference was statistically significant (p<0.05). 
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Table7 Distribution of serum HDL cholesterol levels between the T2DM 
group and control group (n=220) 
 Group N Mean Mean difference 
Student “t” 
test 
p value 
Serum HDL 
cholesterol 
(mg/dl) 
Study 170 45.38 
-0.084 0.959 
Control 50 45.46 
 
Comments:  
Subjects in the T2DM group had mean serum HDL cholesterol levels 
similar to that of controls and this mean difference was not statistically 
significant (p>0.05). 
Table 8 Distribution of serum LDL cholesterol levels between the T2DM 
group and control group (n=220) 
 Group N Mean Mean difference 
Student “t” 
test 
p value 
Serum LDL 
cholesterol 
(mg/dl) 
Study 170 109.01 
-0.568 0.895 
Control 50 109.58 
 
Comments:  
Subjects in the study group had mean serum LDL cholesterol levels 
similar to that of controls and the minor mean difference was not statistically 
significant (p>0.05). 
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Fig 6  Bar chart showing distribution of lipid parameters across the groups 
(n=220) 
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Table 9 Descriptive statistics of various thyroid parameters in the T2DM 
group and control group (n=220) 
Thyroid 
biochemical 
parameters 
Study group (n=170) Control group   (n=50) 
Student ‘t’ 
test  
p value Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Free T3 (pg/ml) 2.46 0.89 2.40 0.49 0.690 
Free T4 (ng/ml) 1.38 0.43 1.32 0.29 0.385 
TSH  (µU/L) 4.36 6.03 2.85 2.33 0.085 
 
Comments: 
Subjects in the study group who had diabetes had similar mean free T3 
and T4levels compared to the controls but had a higher mean TSH levels than 
controls but this mean difference was not statistically significant (p>0.05). 
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Table 10 Distribution of various thyroid parameters in the study group 
and control group (n=220 
Thyroid biochemical 
parameters 
Study group (n=170) Control group   (n=50) ‘z’ test 
p value 
n % n % 
Free T3 
(pg/ml) 
 
Low (<1.4) 7 4.1% 1 2 % 
>0.05 
Normal 
(1.4 to 4.2) 161 94.7% 49 98 % 
High (>4.2) 2 1.2% 0 0 % 
Free T4 
(ng/ml) 
 
Low (<0.8) 11 6.5% 1 2 % 
>0.05 Normal 
(0.8 to 2) 156 91.8% 49 98 % 
High (>2) 3 1.8% 0 0 % 
TSH  
(µU/L) 
Low (<0.3) 3 1.8% 0 0 % 
 
<0.05* 
 
Normal 
(0.3 to 4) 119 70.0% 42 84 % 
High (>4.00) 48 28.2% 8 16 % 
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Comments: 
1. Subjects in the study group who had diabetes had higher proportion of 
subjects in the low and high free T3 and T4group compared to the controls but 
this difference was not statistically significant (p>0.05) 
2. Subjects in the study group had a higher proportion of subjects in the 
low and high TSH group than controls and this difference was statistically 
significant (p<0.05). 
Fig 7 Bar chart showing distribution of thyroid parameters across the groups 
(n=220) 
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Table 11   Distribution of thyroid dysfunction in the study population 
(n=220) 
 
Classification Frequency Percent 
Normal 155 70.5 
Hypothyroidism 17 7.7 
Hyperthyroidism 6 2.7 
Subclinical Hypothyroidism 42 19.1 
Total 220 100.0 
 
Comments: 
 About 19% of the subjects had subclinical Hypothyroidism while 
roughly 8% and 3% of the subjects had hypo and hyperthyroidism, 
respectively. 
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Fig 8  Pie chart showing distribution of thyroid dysfunction across the 
groups (n=220) 
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Table 12   Distribution of thyroid dysfunction in the study group and 
control group (n=220) 
 
 
Classification 
 
Study group (n=170) Control group   (n=50) 
n % n % 
Normal 113 66.5% 42 84.0% 
Thyroid dysfunction 57 33.5% 8 16.0% 
Total 170 100.0% 50 100.0% 
 
Chi-square value: 5.703     df=1 p value= 0.017* 
Comments: 
1. The prevalence of thyroid dysfunction among subjects in the study 
group who had diabetes was 33.5% while it was 16% in the control 
group. 
2. Considering the prevalence of thyroid dysfunction among subjects in the 
study group who had diabetes than the controls, the difference in 
prevalence (33.5% vs 16%) was statistically significant (p<0.05). 
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Table 13. Distribution of thyroid dysfunction in the study group and 
control group (n=220) 
Classification 
Normal 
Study group (n=170) 
Control group   
(n=50) ‘z’ test 
p value 
n % n % 
Normal 113 66.5% 42 84.0% <0.05* 
Hypothyroidism 15 8.8% 2 4.0% >0.05 
Hyperthyroidism 6 3.5% 0 0.0% >0.05 
Subclinical 
Hypothyroidism 
36 21.2% 6 12.0% >0.05 
Total 170 100.0% 50 100.0% >0.05 
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Comments: 
1. Subjects in the study group who had diabetes had higher proportion of 
subjects with hypothyroidism, hyperthyroidism and subclinical 
Hypothyroidism compared to the controls but this difference was not 
statistically significant (p>0.05). 
2. But as a whole when considering the prevalence of thyroid dysfunction 
among subjects in the study group who had diabetes than the controls, the 
difference in prevalence (33.5% vs 16%) was statistically significant 
(p<0.05). 
Fig 9. Bar chart showing distribution of thyroid dysfunction in the study 
group and control group (n=220) 
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Table 14. Distribution of total cholesterol according to the thyroid status 
among diabetic subjects in the study group (n=170) 
 
Chi-square value: 6.796  df = 2  p value:0.033 
Comments:  
Among the study subjects who had diabetes, the subjects with 
Subclinical and clinical Hypothyroidism had higher proportion of elevated total 
cholesterol levels (45% vs. 26% and 17%) in comparison to euthyroid and 
hyperthyroid subjects and this difference was statistically significant (p<0.05). 
Thyroid status 
Total cholesterol (mg/dl) 
Normal (<200) Elevated (>200) Total 
Normal 84 74.3% 29 25.7% 113 100.0% 
Subclinical and clinical 
Hypothyroidism 
28 54.9% 23 45.1% 51 100.0% 
Hyperthyroidism 5 83.3% 1 16.7% 6 100.0% 
Total 117 68.8% 53 31.2% 170 100.0% 
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Fig. 10.   Bar chart showing distribution of elevated total cholesterol 
according to the thyroid status among diabetic subjects (n=170) 
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Table 15. Distribution of triglyceride according to the thyroid status among 
diabetic subjects in the study group (n=170) 
 
Chi-square value: 11.510  df = 2  p value: 0.003 
 
Comments:  
Among the study subjects who had diabetes, the subjects with 
Subclinical and clinical Hypothyroidism had higher proportion of elevated 
triglycerides levels (59% vs 31% and 33%) in comparison to euthyroid and 
hyperthyroid subjects and this difference was statistically significant (p<0.05). 
Thyroid status 
Triglycerides (mg/dl) 
Normal (<150) Elevated (>150) Total 
Normal 78 69.0% 35 31.0% 113 100.0% 
Subclinical and clinical 
Hypothyroidism 
21 41.2% 30 58.8% 51 100.0% 
Hyperthyroidism 4 66.7% 2 33.3% 6 100.0% 
Total 103 60.6% 67 39.4% 170 100.0% 
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Fig 11. Bar chart showing distribution of elevated triglyceride according to 
the thyroid status among diabetic subjects (n=170) 
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Table 16. Distribution of LDL CHOLESTEROL according to the thyroid 
status among diabetic subjects in the study group (n=170) 
 
Chi-square value: 14.888 df = 2   p value:0.001 
Comments:  
Among the study subjects who had diabetes, the subjects with 
Subclinical and clinical Hypothyroidism had higher proportion of elevated 
LDL cholesterol levels (39% vs 14% and 0%) in comparison to euthyroid and 
hyperthyroid subjects and this difference was statistically significant (p<0.05). 
 
 
Thyroid status 
LDL cholesterol  (mg/dl) 
Normal (<130) Elevated (>130) Total 
Normal 97 85.8% 16 14.2% 113 100.0% 
Subclinical and clinical 
Hypothyroidism 31 60.8% 20 39.2% 51 100.0% 
Hyperthyroidism 6 100.0% 0 0.0% 6 100.0% 
Total 134 78.8% 36 21.2% 170 100.0% 
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Fig 12.  Bar chart showing distribution of elevated LDL cholesterol 
according to the thyroid status among diabetic subjects (n=170) 
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Table 17.  Distribution of HDL cholesterol according to the thyroid status 
among diabetic subjects in the study group (n=170) 
 
Chi-square value: 12.106 df = 2   p value:0.002 
Comments:  
 Among the study subjects who had diabetes, the subjects with 
Subclinical and clinical Hypothyroidism had higher proportion of reduced HDL 
cholesterol levels (69% vs 42%) in comparison to euthyroid but hyperthyroid 
subjects had even higher proportion of reduced HDL cholesterol levels (83%) 
and this difference was statistically significant (p<0.05). 
Thyroid status 
HDL cholesterol  (mg/dl) 
Normal (>40 in 
males,>50 in 
females) 
Reduced (<40 in 
males,<50 in 
females) 
Total 
Normal 65 57.5% 48 42.5% 113 100.0% 
Subclinical and clinical 
Hypothyroidism 
16 31.4% 35 68.6% 51 100.0% 
Hyperthyroidism 1 16.7% 5 83.3% 6 100.0% 
Total 82 48.2% 88 51.8% 170 100.0% 
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Fig 13.Bar chart showing distribution of reduced HDL cholesterol 
according to the thyroid status among diabetic subjects(n=170) 
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Table 18.  Distribution of BMI according to the thyroid status among     
                   diabetic subjects in the study group (n=170) 
 
Thyroid status N 
Mean 
BMI 
Std. 
Deviation 
95% Confidence 
Interval for Mean 
Lower  Upper  
Normal 113 25.4462 2.90318 24.9051 25.9873 
Subclinical and clinical 
Hypothyroidism 
51 25.4029 3.20670 24.5010 26.3048 
Hyperthyroidism 6 25.0912 2.75206 22.2031 27.9794 
Total 170 25.4207 2.97598 24.9701 25.8713 
 
ANOVA test was done to test the difference in mean BMI levels between the 
three groups. 
ANOVA test 
p value 0.959 
F statistic 0.041 
Degree of freedom 2 
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Comments: 
1) ANOVA test showed that there was no statistically significant difference in 
mean BMI between the three groups. 
2) Hence the distribution of obesity and overweight was almost similar among 
subjects with and without thyroid dysfunction. This may be due to the fact 
that they were all diabetics and obesity may be present as a pre-existing 
and pre-disposing factor for diabetes and thyroid dysfunction. 
 
Table 19.  Distribution of HbA1caccording to the thyroid status among 
diabetic subjects in the study group (n=170) 
Thyroid status N 
Mean 
HbA1c 
Std. 
Deviation 
95% Confidence 
Interval for Mean 
Lower  Upper  
Normal 113 7.204 1.5664 6.912 7.496 
Subclinical and clinical 
Hypothyroidism 
51 6.939 1.7760 6.440 7.439 
Hyperthyroidism 6 6.350 0.6535 5.664 7.036 
Total 170 7.094 1.6145 6.850 7.339 
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ANOVA test was done to test the difference in mean HbA1c levels between the 
three groups. 
ANOVA test 
p value 0.324 
F statistic 1.133 
Degree of freedom 2 
 
Comments: 
1) ANOVA test showed that there was no statistically significant difference in 
mean HbA1c between the three groups. 
2) Hence the distribution of HbA1c was almost similar among subjects with 
and without thyroid dysfunction.  
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Table 20. Gender distribution of thyroid status among diabetic subjects in 
the study group (n=170) 
 
 
Chi-square value: 10.193 df = 3  p value: 0.017 
Comments: 
 Among the study subjects who had diabetes, female subjects had higher 
proportion of subclinical and clinical Hypothyroidism (combined: 40.2% vs 
20.5%) in comparison to euthyroid and hyperthyroidism was also more 
common in females than males (4.9% vs 2.3 %) and this difference was 
statistically significant (p<0.05). 
Thyroid status 
Gender 
Females Males 
Normal 45 54.9% 68 77.3% 
Hypothyroidism 11 13.4% 4 4.5% 
Hyperthyroidism 4 4.9% 2 2.3% 
Subclinical 
Hypothyroidism 
22 26.8% 14 15.9% 
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Fig 14.  Doughnut chart showing gender distribution of thyroid status 
among diabetic subjects in the study group (n=170) 
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DISCUSSION 
  Diabetes mellitus is the most important health problem in populations 
worldwide and inspite of advances in treatment, a huge number of patients 
present with complications owing to poor glycaemic control. One of the vital 
factors that contribute to deprived glycaemic control is thyroid dysfunction, 
which tends to happen down with diabetes mellitus. This study sought to find 
out the prevalence of thyroid dysfunction in people with type 2 diabetes 
mellitus in our region. 
DM is a multi-factorial disorder. There is a complex interaction between 
DM and thyroid disorder. Because of insulin and thyroid hormones are closely 
involved in cellular metabolism, any abnormal levels of one of them may result 
in the functional derangement of other. 
In our study, we demonstrated a 33.5% prevalence of thyroid disease 
among 170 DM subjects compared to 16% in control group. Among this, 
21.2% had subclinical hypothyroidism.it is similar to many studies like Palma 
et al, vinu vij et al, celani et al, singh et al and udiong et al. 
Next to SCH, hypothyroidism was common (8.8%) followed by 
hyperthyroidism (3.5%).So total hypothyroidism is more common (30%) than 
hyperthyroidism. This also supported by various study like moghetti et al 76 
which showed 89% hypothyroidism and 11% hyperthyroidism. 
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The reasons  for both high and low level of thyroid hormones in diabetes 
are the modified TRH synthesis and release. This also due to various 
medications used for DM. Many studies concluded that the treatment of DM by 
sulfonylurea leads to an increase in occurrence of goitre and hypothyroidism . 
77, 78 
SCH is defined as an above normal level of serum TSH with normal free 
thyroxine level. 
SCH can causes outbreaks of sensitive functions like left ventricular 
diastolic dysfunction, lack of ovulation, increased expression of LDL receptors, 
and decreased HDL receptors. It is a threat indicator used for cardiovascular 
disease especially for atherosclerosis and coronary heart disease.SCH also 
independently increase the risk of insulin resistance mainly in muscles and 
adipose tissue. 
So normalization of TSH level will decrease the post prandial blood 
glucose, HbA1c and lipids level. Timely diagnosis of SCH in DM patients and 
adequate treatment is very important to prevent complications.    
In our study, serum lipid levels were elevated in DM subjects compared 
to normal subjects. A linear raise in serum total cholesterol, LDL Cholesterol 
and triglycerides, and linear decrease in serum HDL Cholesterol were 
observed. This also similar to Sawant et al 79 and  Saha HR et al 80 studies. 
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 The study population was predominantly male, but the prevalence of 
hypothyroidism was high in female at 40.2% and males at 20.5%. This is 
comparable to studies of Papazafiropoulou et al 81, Celani et al as well as 
Michalek et al 82 in which they also reported prevalence of thyroid disorders 
higher in diabetic females as compared to diabetic males, who found female 
predominance of 60%.This could be partly explained by the fact that 
autoimmune diseases tend to occur predominantly in females. 
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SUMMARY  
The review of literature of many studies all over the world concluded 
that thyroid dysfunction and DM co-exists in significant number of patients. A 
recent finding shows that subclinical hypothyroidism and DM add to major 
problems such as retinopathy and neuropathy. 
 In our study overall 33.5%   occurrence of thyroid dysfunction was 
found in Diabetic patients. Among this, highest prevalence was 21.2% of 
subclinical hypothyroidism followed by8.8% of hypothyroidism and 3.5% of 
hyperthyroidism. There was a positive association of TSH with LDL-c and TC. 
Further investigations are needed to understand the mechanism of lipid 
metabolism in Type 2 DM with respect to Thyroid function.  
  The unrevealed thyroid dysfunction may harmfully impact on Diabetes 
& its complications. Hypo Thyroidism has most important negative effect on 
glyceamic control and so potentially influence the complications. 
Our results demonstrate that finding of   thyroid dysfunction level 
especially sub clinical hypo thyroidism and its association with biochemical 
abnormalities like poor glycemic control, dyslipidemia, early will enable better 
treatment and prevention or delay the onset of complications. The American 
thyroid association guidelines recommend thyroid test in Type2 DM patients at 
the time of diagnosis and to be repeated at least every five years Hence it is 
suggested for routine screening for thyroid function in all type 2 DM patients.. 
A sensitive TSH assay is the screening test of choice. 
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CONCLUSION 
Our study have proved that increased prevalence of hypothyroidism 
especially subclinical hypothyroidism in T2DM patients which is  consistent 
with many previous studies, hence it may be advisable to check thyroid status 
in every T2DM patients for the better management of T2DM and to reduce its 
complications. 
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LIMITATION OF THE STUDY 
Due to financial constraints:  Unable   to do thyroid autoantibody assays 
in this population. 
Further research needs to be done with regards to thyroid antibodies 
bearing in mind strong family history and high prevalence of thyroid 
dysfunction in this population.  
Our sample size was small and the limited observation period do not 
allow definite conclusion from our data. So we need more comprehensive study 
with large sample population and long period. That would be more informative. 
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CASE RECORD FORM 
 
A Study on Thyroid Profile Status in Type 2 Diabetes Mellitus 
 
Case no   :       Date   : 
Name    : 
Op/ Ip no   :       unit   : 
        
Age    : 
Sex    : 
Location   : Urban / Rural 
Occupation   :  
 
Height :    Weight:    BMI: 
 
Complaints   : 
 
H/o illness   : 
 
 
Duration of DM  : 
 
 
 
Under Medication or Not : 
 
If, Yes - Drug Details  : 
 
 
 Past History  : 
 Personal History : 
 Family History : 
 
 
General Examination  : 
 
 
 
 
Systemic Examination : 
 
 
 
Date of sample collection : 
 
Date of Analysis  : 
 
INVESTIGATION : 
 
 Diabetic profile        : (F) Glucose     (PP) Glucose 
    HbA1c :        
  
 Renal profile            : Urea:                Creatinine :   
  
 
 Lipid profile             : Tc   HDLc :   LDLc : 
    Triglycerides:        
             
   
 Thyroid profile         : FT 3:    FT 4 : 
    TSH:       
 
 
             
           Signature of Investigator 
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1 57 M 165 70 25.711662 120 80 150 356 6 28 1.3 160 87 78 57 1.5 1.6 1.3
2 60 F 160 78 30.46875 136 90 233 341 9.6 15 0.9 189 73 163 39 4 1.9 8.1
3 45 M 175 65 21.22449 120 80 83 188 5.9 24 1 165 111 84 47 3.9 1.5 1
4 38 F 142 60 29.756001 110 70 341 486 10.4 15 0.7 190 234 118 35 2 1.7 1.7
5 60 M 165 80 29.384757 140 78 160 241 6.4 18 0.8 153 84 87 47 2.8 1.4 1.2
6 58 F 150 60 26.666667 140 86 110 153 5.9 19 0.7 218 117 139 51 2.9 1.4 1.2
7 59 M 164 70 26.026175 130 80 100 130 6 16 0.8 156 64 91 39 2.2 1.6 1.2
8 55 F 155 54 22.476587 130 86 95 119 5.2 23 0.7 185 127 112 40 2.2 1.4 18.9
9 58 F 152 60 25.969529 140 94 99 174 6.3 29 0.9 284 222 105 51 3.2 1.4 1.3
10 44 F 145 65 30.915577 140 90 123 150 5.6 17 0.8 192 124 113 41 3.1 0.9 13.3
11 49 F 152 64 27.700831 130 90 138 160 6.2 20 0.8 190 136 109 40 2.8 1.2 4
12 47 F 156 70 28.763971 120 80 218 378 10.9 35 0.9 208 265 105 69 2.5 1.7 5.8
13 60 M 172 50 16.901028 146 80 131 266 6.8 27 0.9 166 112 95 38 3 1.3 4.5
14 53 M 165 72 26.446281 130 96 168 260 8.6 29 1 220 116 136 50 1.4 1.4 2.4
15 57 F 150 62 27.555556 130 70 172 301 10.8 17 0.7 281 98 105 52 2.1 1.5 1.8
16 52 M 180 78 24.074074 140 90 145 315 10.6 22 0.6 169 80 96 49 3.1 1.5 1.8
17 61 M 163 70 26.346494 130 90 141 271 6.5 31 0.9 127 366 73 18 1.9 1.6 4.4
18 65 M 165 72 26.446281 140 90 225 463 9.8 42 1 202 103 136 34 2.7 1.7 4.3
19 37 M 172 75 25.351541 120 80 85 161 5.7 18 1 192 168 108 44 3 1.6 3.9
20 43 M 165 70 25.711662 110 70 122 214 6.2 19 1 179 182 108 54 3.4 1.5 0.7
21 46 F 165 72 26.446281 160 74 215 339 9.2 15 0.7 163 82 96 51 2.3 1.1 3.6
22 65 M 160 64 25 130 90 104 249 6.6 26 1 139 157 74 35 2.3 2.1 3.6
23 45 M 174 65 21.46915 130 86 125 230 6.9 16 1.1 190 117 110 45 4.5 1.3 1.2
24 62 M 162 55 20.957171 110 70 298 400 10.2 20 1.2 229 132 144 36 2.1 1.3 1.7
25 60 F 165 75 27.548209 156 94 138 229 7 25 0.9 158 154 76 46 2.2 1.4 2.3
26 63 F 155 48 19.979188 110 80 163 322 7.6 16 0.8 214 93 124 59 1.9 0.9 2.4
27 37 F 154 60 25.299376 110 70 235 345 9.6 19 0.7 204 118 146 46 1.3 1.2 4.1
28 44 M 175 65 21.22449 136 80 293 427 9 23 1.1 232 212 137 38 2.7 1.7 2.3
29 37 M 160 71 27.734375 146 84 316 454 10.2 25 1 166 84 82 57 1.8 1 21.5
30 70 M 160 48 18.75 160 90 144 194 5.7 21 1.6 235 80 145 49 2.2 1.4 2
31 58 M 160 64 25 130 80 106 164 5.8 28 1.3 249 181 151 38 2.4 1.5 6.9
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32 43 F 156 60 24.654832 130 86 94 168 5.9 15 0.6 149 134 75 38 2.9 1.4 1.1
33 38 F 158 57 22.832879 110 70 93 185 5.7 25 0.8 224 127 169 58 1.5 0.5 35.5
34 78 M 170 70 24.221453 140 90 98 162 5.8 23 1 143 66 81 38 2.9 1.4 4
35 36 M 165 65 23.875115 150 90 101 162 5.8 15 0.9 307 102 196 51 2.6 1.6 4.5
36 33 M 164 57 21.192742 110 70 204 294 6.8 23 0.9 183 193 101 53 2.6 1.5 1.6
37 53 M 162 74 28.196921 130 90 138 276 6 20 1.2 137 128 76 37 2.3 1.3 3.6
38 38 M 165 72 26.446281 126 80 191 373 6.9 16 0.8 163 172 93 47 2.7 1.8 4
39 60 F 150 65 28.888889 140 90 312 424 10.3 28 1 182 149 110 39 2.2 1.4 0.8
40 62 F 152 68 29.432133 130 80 117 316 5.5 24 0.8 202 139 96 42 11.6 4.7 0.05
41 57 F 150 65 28.888889 150 84 125 196 5.4 17 0.7 190 103 108 46 2.8 1.3 2.7
42 46 M 170 65 22.491349 130 80 237 366 10.3 24 0.9 182 94 116 35 2.3 1.3 0.8
43 63 M 164 62 23.051755 130 90 127 252 6.3 25 0.9 157 273 94 32 3 1.2 7.2
44 52 F 160 68 26.5625 130 96 113 123 5.8 15 0.7 220 74 162 65 2.7 1.4 9.7
45 59 F 150 64 28.444444 110 70 135 199 6.2 15 0.8 136 210 72 58 2.4 1 3
46 49 F 150 48 21.333333 120 70 106 167 5.7 19 0.7 169 235 103 45 2.6 1.5 1.5
47 45 M 168 65 23.030045 146 90 139 164 5.6 25 1 211 243 118 39 2.7 1.6 1.5
48 50 F 150 62 27.555556 130 70 221 375 9.2 15 0.7 156 95 84 44 2.3 1.5 3.6
49 67 F 145 60 28.537455 110 60 120 145 6.1 16 1.1 147 152 71 36 1.6 0.7 4.5
50 65 F 150 62 27.555556 140 90 104 145 5.7 20 0.8 245 243 149 39 2.2 0.3 2.7
51 55 M 170 67 23.183391 130 85 118 142 5.4 19 1.4 102 210 46 30 0.5 0.2 37.5
52 42 M 160 75 29.296875 120 70 166 290 6.3 15 1 195 173 114 39 2.4 1.6 4.1
53 35 F 150 62 27.555556 150 80 388 394 8.4 28 0.9 266 78 96 41 2.6 1.5 0.9
54 47 F 147 60 27.766209 130 70 128 219 7.2 26 0.9 225 160 131 44 2.2 1.2 4
55 56 F 150 63 28 130 90 119 264 7.4 15 0.9 138 125 73 41 2.6 1.5 1.2
56 40 M 165 69 25.344353 126 86 87 162 5.6 21 1.1 208 117 166 48 1.9 0.7 3.5
57 49 F 162 58 22.10029 110 70 115 120 5.3 16 0.8 190 176 106 40 2.6 1 10.3
58 38 M 167 76 27.250887 150 80 83 155 5.7 25 0.8 249 93 92 36 2.4 1.6 1.5
59 66 M 176 90 29.054752 140 90 103 196 6.2 22 1 134 97 72 36 2.8 1.1 2.1
60 54 F 147 50 23.138507 140 70 114 136 5.9 29 0.7 162 151 82 44 2.9 1.9 0.05
61 50 F 152 67 28.999307 150 86 132 126 5.7 19 0.8 315 187 188 58 3.1 0.4 6.7
62 43 F 146 52 24.394821 110 70 91 102 5.2 15 0.7 186 134 111 42 2.3 1.3 1.8
63 38 F 160 80 31.25 110 80 119 167 7.8 16 0.7 193 119 113 40 2.7 1.8 0.6
64 58 F 150 57 25.333333 120 80 129 226 11.6 27 0.8 147 271 111 43 2.7 0.7 20.8
65 45 F 152 60 25.969529 120 70 176 256 8.4 21 0.7 161 132 93 38 2 1 2.4
66 60 M 170 76 26.297578 130 86 90 182 6.3 15 0.9 186 97 118 37 2.4 0.9 3
67 35 M 158 60 24.03461 140 80 371 564 10.8 18 0.9 151 101 79 46 1.9 1.8 2.5
68 47 M 170 72 24.913495 120 90 229 355 9.6 16 0.9 177 174 100 36 2 1.4 2.6
69 52 F 140 52 26.530612 140 90 153 201 7.2 15 0.8 162 73 80 47 2.3 1.8 0.1
70 33 M 157 65 26.370238 126 80 101 217 7 17 1.2 172 222 92 49 2.2 1.3 2.9
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71 70 M 165 60 22.038567 128 76 103 248 7.4 24 1 148 62 83 39 2.5 1.3 1.7
72 49 M 165 58 21.303949 140 80 569 674 11.6 29 1.1 278 74 100 47 2.5 1.9 3.3
73 40 F 154 63 26.564345 120 80 174 369 8.6 17 0.8 200 199 95 44 2.2 1.2 2.4
74 63 F 150 60 26.666667 140 96 93 302 8 15 0.9 155 227 70 48 2.8 1.5 4.8
75 45 F 149 67 30.178821 110 70 145 179 7.2 28 0.7 276 187 95 54 2.2 1.4 1.4
76 42 F 158 65 26.037494 120 86 222 437 8.6 16 0.8 145 160 94 40 3.4 1.3 5.8
77 57 F 160 58 22.65625 140 80 91 171 5.7 33 0.9 277 321 141 62 2.1 1.3 5
78 46 F 154 75 31.62422 120 76 160 201 5.9 23 1 230 330 170 46 0.9 0.6 37.2
79 65 M 168 74 26.218821 140 80 169 294 8.5 36 0.9 181 189 96 37 1.2 1.4 5.9
80 67 M 165 68 24.977043 130 86 145 196 6 25 0.8 122 69 56 40 2.5 2.1 1.2
81 48 M 158 64 25.636917 130 90 99 162 5.8 16 1 211 127 118 41 2.3 1.6 2.3
82 67 F 155 63 26.222685 110 80 126 250 6.3 24 0.8 154 170 84 39 2.6 1.1 0.9
83 56 M 165 60 22.038567 136 90 125 220 6.7 15 1 177 98 104 37 3 1.5 1.7
84 43 F 145 63 29.964328 120 80 110 193 6.2 16 0.8 241 224 142 45 3.1 1.2 1.2
85 66 M 160 72 28.125 140 96 100 160 5.8 18 1.2 185 213 99 36 1.3 0.3 36.5
86 55 F 148 60 27.392257 120 90 229 363 8.3 21 0.7 177 135 99 51 2.2 1.8 1.1
87 33 M 174 68 22.460034 130 70 139 212 7.2 22 0.8 198 92 119 38 2.1 1.6 2.6
88 65 M 156 54 22.189349 110 70 173 422 8.8 44 1 172 73 83 62 1.7 1.8 1.1
89 63 F 154 75 31.62422 150 96 169 198 6.2 29 0.9 194 129 98 71 3 1.9 1.6
90 48 F 160 74 28.90625 130 80 217 402 8.9 19 0.7 208 138 134 62 2.1 1.5 1.8
91 37 F 164 58 21.564545 110 70 160 350 9.4 23 0.6 180 119 105 42 2.6 2 6.4
92 46 M 162 62 23.624447 130 80 122 265 6.4 20 0.9 172 82 110 35 2.4 1.2 6.2
93 51 M 170 74 25.605536 130 94 102 184 5.8 22 1 171 117 127 39 2.3 1.2 3
94 50 F 154 63 26.564345 130 80 278 349 8.4 24 0.8 211 87 130 41 2 1.2 3.9
95 58 M 168 78 27.636054 140 96 123 252 6.8 21 1 160 113 98 50 2.1 1.7 1.9
96 68 M 164 73 27.141582 130 70 104 233 6.2 37 0.9 190 150 108 50 2.8 1.6 1.1
97 38 F 150 64 28.444444 120 80 84 162 5.8 17 0.8 115 108 78 54 2 1.7 4
98 46 F 168 54 19.132653 130 80 428 705 10.4 28 1.3 246 187 174 35 2.3 1.7 4.9
99 57 M 168 64 22.675737 120 86 487 629 10.6 35 1.3 274 194 105 53 2.1 1.4 1.6
100 58 M 160 68 26.5625 130 80 94 160 5.8 46 1.2 131 65 69 30 1.7 1.2 4.5
101 59 M 162 65 24.767566 130 80 115 128 5.7 25 0.9 149 103 84 38 2.5 1.2 3.9
102 61 F 157 60 24.341758 120 80 84 153 5.7 17 0.7 219 124 132 58 2.3 1.4 1.1
103 56 F 160 65 25.390625 110 70 97 171 5.9 19 0.7 198 166 124 65 2.7 0.8 2.2
104 55 M 160 62 24.21875 110 70 176 200 8.2 35 0.9 221 189 136 36 2.5 1.4 1.3
105 48 F 158 63 25.23634 120 76 87 143 6 19 0.7 183 129 93 54 2.2 1.3 2.6
106 46 M 175 68 22.204082 140 80 229 355 8.2 16 0.9 177 174 100 36 2 1.4 2.6
107 56 F 157 68 27.587326 100 74 108 162 6 30 0.8 171 134 114 38 2.3 1.1 2.3
108 61 F 150 69 30.666667 120 70 125 214 6.2 25 0.9 194 150 108 54 2.7 1.3 2.4
109 42 M 174 76 25.102391 138 60 137 255 6.4 15 1 208 157 131 41 1.9 2 8
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110 41 M 165 64 23.507805 130 90 117 232 6.4 24 1.1 172 176 114 41 3.1 1.7 0.7
111 33 F 155 58 24.141519 130 70 119 232 6.6 15 0.8 189 98 97 41 3.1 1.5 3.1
112 43 M 170 65 22.491349 140 80 112 192 6.8 21 0.9 101 130 129 40 2 1.2 2.1
113 45 M 174 70 23.120624 100 70 212 318 9.3 18 0.8 239 261 151 42 2 1.4 4.4
114 38 M 160 65 25.390625 140 90 263 382 10.4 17 0.9 205 138 132 45 2.3 1.8 3.1
115 46 M 168 62 21.96712 120 90 176 357 9.6 17 0.9 191 100 124 42 2.4 1.5 3.2
116 55 M 165 58 21.303949 130 86 172 222 6.7 22 1 279 297 168 43 2.3 1.9 10.4
117 39 M 165 74 27.1809 136 90 113 157 5.8 20 1 218 162 143 46 2.2 1.2 2.8
118 61 M 160 63 24.609375 130 78 122 168 5.2 19 0.9 119 244 72 40 2.4 1.5 8
119 49 M 168 62 21.96712 130 68 154 310 6.8 17 1 181 161 116 43 2.4 1.3 1.2
120 57 M 165 70 25.711662 130 86 168 363 8.1 22 0.8 167 164 113 38 2.1 1.7 2.6
121 44 F 145 60 28.537455 130 80 138 330 7.3 16 0.8 165 97 110 44 2.4 1.1 3.4
122 44 M 165 65 23.875115 130 80 101 141 5.4 20 1.1 160 118 100 50 1.3 0.9 4.6
123 66 F 147 57 26.377898 120 80 115 201 5.7 16 0.9 169 128 95 45 2.2 1.3 2.4
124 80 M 168 60 21.258503 146 94 100 143 5.4 25 1.1 166 74 97 51 1.9 1.4 3.7
125 65 M 170 64 22.145329 140 76 98 155 6 18 0.9 228 123 132 52 2.4 1.1 1.4
126 60 F 145 60 28.537455 130 90 151 187 6.5 22 0.9 183 128 165 43 2.1 1 6.9
127 39 M 175 64 20.897959 120 76 95 146 6 29 1.1 160 111 103 47 1.7 1.6 1.3
128 53 F 145 60 28.537455 140 94 92 151 6.2 24 0.8 195 131 132 57 2.5 1 2.8
129 55 M 168 74 26.218821 140 80 107 225 6.1 27 0.8 172 94 130 41 2.5 1.4 1
130 64 M 160 74 28.90625 130 90 173 283 7.2 23 0.9 126 95 76 52 2.3 1.6 2.7
131 46 M 164 60 22.30815 140 84 130 192 5.8 27 0.9 169 108 109 46 2.8 1.8 2.8
132 52 F 147 63 29.154519 140 80 213 340 7.4 17 0.8 182 244 104 40 2.5 1.8 1.7
133 52 M 164 57 21.192742 136 80 114 176 6.1 19 0.9 177 178 98 54 2.6 1.5 2.2
134 39 F 153 62 26.48554 120 70 114 134 6.2 16 0.8 169 164 96 58 2.2 1.3 2.2
135 67 F 155 50 20.811655 140 80 200 310 7.9 18 0.7 135 209 76 58 2.3 1.6 2.5
136 36 M 170 68 23.529412 110 70 253 329 8.5 23 0.8 194 184 129 47 2.6 1.3 2.6
137 59 M 160 53 20.703125 130 80 110 186 5.5 16 0.9 142 110 91 39 2.5 1.4 17.1
138 48 F 150 60 26.666667 120 80 297 438 7.8 17 0.7 177 97 97 67 2.4 1.4 2.8
139 44 M 165 68 24.977043 130 84 109 161 5.8 16 0.9 155 87 109 49 2.6 0.9 3.5
140 43 M 168 72 25.510204 130 76 281 522 9.2 28 1.1 169 126 119 39 2.4 1.5 3.5
141 48 M 158 60 24.03461 140 80 100 110 5.5 22 0.8 204 98 142 48 2.4 1.3 6.1
142 43 M 171 68 23.255019 130 90 90 154 5.9 17 1.1 177 135 122 43 2.9 1.1 2.7
143 40 M 165 68 24.977043 110 80 146 197 6.1 17 1 169 224 103 46 2.2 1 1.7
144 49 M 174 63 20.808561 130 70 191 248 7.1 16 1.1 184 76 132 42 2.5 1.5 1.6
145 61 M 160 59 23.046875 160 94 127 136 5.5 33 0.8 163 98 115 31 2.7 1.7 7.7
146 52 M 166 74 26.854406 140 90 262 370 7.8 28 1.2 136 105 82 46 2.8 1.2 2
147 47 F 148 64 29.218408 120 84 124 161 7.1 20 0.9 196 154 97 40 2.5 1.5 1.7
148 60 F 154 68 28.672626 130 94 92 133 5.9 21 1 210 170 105 39 2.5 1.4 5.1
A Thyroid Profile status in type 2 Diabetes Mellitus - Case Group
149 40 F 150 70 31.111111 140 80 168 247 8.7 24 0.9 196 172 86 40 2.5 0.7 4.1
150 62 M 170 60 20.761246 130 94 208 260 6.8 15 1 176 180 90 36 2.6 1.4 2.1
151 39 F 160 74 28.90625 140 86 120 136 5.7 15 1 211 78 110 67 2 1.6 6.1
152 45 F 144 64 30.864198 120 80 102 146 5.3 29 1 226 124 127 57 2 1.3 2
153 42 M 168 70 24.801587 140 90 202 223 10.9 16 0.9 89 82 48 47 2.9 1.7 3.1
154 60 F 163 65 24.464602 130 76 410 572 9.8 25 1 249 152 160 41 2.3 1.1 6.4
155 40 F 155 63 26.222685 130 74 100 192 5.7 15 0.8 254 174 151 51 1 0.9 1.9
156 48 F 145 63 29.964328 110 70 124 153 5.9 15 0.8 157 110 80 43 2.6 1.3 2.5
157 34 F 160 49 19.140625 120 70 110 147 6.3 20 0.8 167 245 74 40 1.7 0.5 6.8
158 50 F 160 73 28.515625 140 80 130 182 7 26 0.8 244 120 99 61 2.6 1.3 3.7
159 56 F 156 60 24.654832 130 80 137 161 8.1 20 0.8 240 139 98 67 2.2 1 1.9
160 35 F 158 64 25.636917 110 70 169 204 7.4 24 0.8 210 164 98 42 4.2 1.5 5.1
161 32 F 152 65 28.133657 120 80 110 142 6.3 22 0.8 173 154 76 42 2.2 1.2 6
162 44 F 154 60 25.299376 130 80 148 196 5.9 25 0.8 220 111 192 52 2.7 1.3 5.4
163 45 F 154 56 23.612751 120 80 218 294 9.3 16 0.8 139 89 66 67 2.4 1.3 3.4
164 43 F 160 56 21.875 130 90 95 160 5.2 15 0.8 186 114 94 43 3 1.3 1.4
165 58 M 162 64 24.386526 120 80 98 162 6.4 16 1 132 279 70 29 2.9 1.3 9.4
166 47 F 154 70 29.515939 140 90 82 223 6.7 23 0.8 159 62 74 50 2.3 1.6 2.6
167 46 M 175 72 23.510204 130 90 120 210 7 27 1 240 124 146 44 2.8 1.7 1.6
168 55 F 154 60 25.299376 130 80 160 242 7.2 21 0.7 213 126 127 59 2.3 1 2.7
169 66 M 163 62 23.335466 120 80 114 171 6.2 35 1.2 198 208 127 51 2.7 1.9 1.6
170 55 M 158 60 24.03461 110 80 160 202 6.8 43 1.5 200 148 125 50 1.8 1.6 1.6
A Thyroid Profile status in type 2 Diabetes Mellitus-Control Group
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1 46 F 154 46 19.396188 110 70 92 123 5.3 18 0.7 210 123 120 41 2.1 1.5 2.9
2 40 M 160 64 25 120 86 98 103 5.2 21 0.8 114 142 80 43 3.1 1.5 2.8
3 40 F 158 54 21.631149 110 70 87 112 4.8 15 0.9 152 138 75 43 2.8 1.2 3.5
4 66 M 162 68 25.910684 140 80 92 107 5 30 1.4 161 87 103 29 2.5 1.4 1.3
5 47 F 156 58 23.833005 110 70 81 98 4.8 15 0.8 182 84 100 38 1.6 1.3 4.7
6 35 M 164 60 22.30815 110 80 70 94 5.4 21 0.8 240 109 130 57 3 1.3 1.5
7 49 M 168 63 22.321429 140 90 83 101 5 27 0.9 206 190 120 37 3.4 0.8 7.7
8 45 M 158 58 23.233456 130 80 84 107 5.1 21 1 203 148 122 40 2.7 1.1 3.4
9 46 M 157 64 25.964542 110 70 85 129 4.9 18 1 170 79 88 43 2.4 1.2 1
10 35 F 152 66 28.566482 110 80 91 124 4.9 15 1 195 88 106 43 3 1.6 2.3
11 38 F 160 72 28.125 110 80 73 106 5.1 15 0.7 181 117 91 49 2.6 1.6 0.9
12 46 M 168 70 24.801587 130 80 71 94 4.5 15 1.2 203 257 113 35 1.7 1.2 2.3
13 53 F 164 59 21.936347 120 80 93 104 5.7 19 0.6 188 114 119 33 2.7 0.9 1.7
14 75 M 160 70 27.34375 140 90 95 105 5 25 1 156 59 99 37 1.8 1.6 3.5
15 41 M 148 60 27.392257 110 70 102 113 5.5 23 1 214 77 126 60 2.2 1.9 1.4
16 54 M 156 68 27.942143 110 70 88 99 4.8 16 0.6 170 84 99 116 2 1.4 6.4
17 39 M 162 58 22.10029 120 80 97 109 5.3 21 1 175 129 95 48 2.9 1.6 1.6
18 46 M 154 60 25.299376 120 70 99 106 5.2 24 0.8 181 64 105 46 2.7 1.5 1
19 39 M 152 68 29.432133 120 70 94 103 5 16 1.1 188 248 105 40 1.6 1.9 1.9
20 45 F 152 58 25.103878 110 70 90 104 5.2 16 0.7 168 117 98 41 2.3 1.2 2
21 48 M 172 64 21.633315 110 70 94 107 5.4 17 0.8 209 116 128 49 2.2 1.7 1.9
22 45 M 162 62 23.624447 120 70 91 100 5 20 1 181 116 119 42 2.6 1.2 2.4
23 48 F 151 63 27.630367 130 80 96 102 4.8 22 0.8 161 68 109 41 2 1.2 4.4
24 48 M 176 59 19.047004 130 90 90 134 5.2 19 0.9 216 141 153 43 2.1 1.3 4.9
25 36 F 150 57 25.333333 110 70 98 114 5 16 0.7 214 205 125 40 2.2 1.5 1.9
A Thyroid Profile status in type 2 Diabetes Mellitus-Control Group
26 55 M 168 72 25.510204 140 80 100 111 5.3 53 1.4 156 75 98 44 2.8 1 2.5
27 64 M 165 63 23.140496 130 90 100 131 5.1 33 1.1 155 82 90 46 2.4 1.9 1.4
28 44 M 160 58 22.65625 110 70 101 141 5.4 20 1.1 160 118 100 50 1.3 0.9 4.6
29 63 M 164 68 25.28257 140 80 99 126 4.9 28 1 156 182 103 35 2.4 1.3 0.7
30 61 F 148 60 27.392257 130 90 104 125 5.4 18 0.8 142 106 86 47 2.1 1.2 2.2
31 49 M 170 68 23.529412 110 80 97 131 4.9 19 1.1 185 111 111 61 2.5 1.2 3.8
32 52 M 172 70 23.661439 120 80 88 108 5.4 31 1.2 135 68 90 34 3.2 1.6 3.7
33 45 F 162 58 22.10029 100 70 90 104 5.2 16 0.7 168 117 98 41 2.3 1.2 2
34 49 M 168 65 23.030045 110 90 94 103 5 16 1.1 188 248 108 40 1.6 1.9 1.9
35 47 F 150 50 22.222222 130 70 89 137 5.2 24 0.8 189 104 97 70 1.6 1.4 15
36 52 M 168 64 22.675737 130 76 82 112 4.9 19 0.9 201 136 119 42 2.7 1.3 1.5
37 49 M 174 68 22.460034 110 80 97 109 5.3 21 1 175 127 95 48 2.9 1.6 1.6
38 45 M 164 70 26.026175 120 86 90 99 4.7 17 0.9 219 129 147 48 2.3 1 1.3
39 80 M 170 62 21.453287 130 80 100 133 5.4 25 1.1 166 74 97 51 1.9 1.4 3.7
40 48 M 162 59 22.481329 120 76 85 103 4.8 21 1.1 218 81 155 37 2.3 1.2 3.2
41 48 M 166 69 25.039919 130 84 91 99 4.4 15 0.9 151 66 94 42 2.6 1.3 0.8
42 53 F 150 62 27.555556 120 80 101 134 5.1 15 0.7 242 83 144 59 3.1 1.3 2.5
43 52 M 172 68 22.985398 140 84 85 100 4.5 19 1.1 254 84 177 50 2.6 1.4 1.7
44 61 M 154 60 25.299376 130 80 104 112 5 24 1.1 192 91 119 38 2.4 0.8 3.2
45 54 M 170 66 22.83737 120 84 100 110 5.1 15 0.9 145 135 96 34 2.3 1.1 2
46 45 M 164 58 21.564545 130 76 96 101 4.9 28 0.9 142 59 92 38 2.8 1 2
47 58 F 152 60 25.969529 110 80 105 120 5.1 15 0.7 185 93 102 47 3.4 1.5 3
48 51 M 164 62 23.051755 130 76 84 122 4.7 21 1 161 67 80 67 1.8 1 1.4
49 49 F 154 62 26.142688 110 80 82 96 4.3 30 0.8 221 248 151 33 2.1 0.6 6.6
50 50 M 168 60 21.258503 130 84 96 110 5.4 19 1.1 145 79 102 37 2.6 1.5 0.9
  
 
x g ;G jy ; g b t k;; ; ;; ; ;; ; ;  
nr d;id kUj;J tf;fy;Y}h p kUj;J tkid kw ;Wk; M uh a;r;r p ikaj;jpd; caph; 
Ntjpapay ; J iw apy; e lj;j g ;gL k; “e Ph pop T Ne h ah spfspy ; ij u h a;L  `hh ;Nkh d; 
g h pNr hj id” – y ; g q;Nfw ;Fkh W cq;fis Nfl;L f; nfh s;fpNw h k;.  
 
 
 , g;g h pNr h j idf;F r k;kjpg;g J cq;fs; tpUg;gj;ij g ; ngh Wj;jJ . 
 , r;Nr h j idf;F fl;lzk; fpilah J . 
 fl;lh ak; VJ k; , y;iy .  
 g h pNr hj idapy pUe ;J ve ;Ne uKk; tpyf j q;fSf;F K O ch pik cz;L . 
 
 
, e;j  M a;tpd; K bTfs; kUj;J tk; kw ;Wk; tpQ;Qh d K d;Ndw ;w j;jpw ;F 
cj Tk; vd;W fUJfpd;Nw h k;.  , itfis NtW vjw;Fk; g ad;g L j;j g ;g l 
kh l;lh J vd cWjpaspf;fpNwh k;. 
 
xg ;Gj y ;; ;; ;; ;  
 
 e h d; jpU/jpUkjp/nry ;tp/ _________________________________________________ 
K fth p____________________________________________________________________________ 
___________________________________________________________e h s;____________________ 
md;W Nkw ;fz;l M a; Tf;fh f j fty; g btj;jpid g bj;J, Nfl;L  Gh pe ;J  nfh z;L 
, e;j  M uh a;r;r pf;F Njitah d Nrh j idf;F vd;dplk; , Ue ;J  4kpy p.  ,u j;jk; 
vL j;J f; nfh s;s mDkjpf;fpNw d;.  vd; kdg ;G+h ;tkh d r k;kj j;ij  mspg;g Nj hL  , e;j  
M a;tpd; K bTfis kUj;J tk; kw ;Wk; tpQ;Qh d Neh f;fj;jpw ;F g ad;g L j;j  
xg ;Gj y; mspf;fpNw d;. 
 
e L epiy  rh l;r papd; ifnah g ;g k; 
g q;Nfw;g h sh ; ifnahg;g k; 
 
 
 
 
 
M a;th sh; / r k;kjk; ng Wg th; ifnah g;g k; 
 
 
nr d;i d kUj;J tf;fy ;Y}h p kUj;J tkid kw ;Wk ; Mu h a;r ;r p ikak ;; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ;, 
, Uq;f@H; ;; , jpUr ;r pu hg ;gs;sp ; ; ;; ; ;; ; ; – 621 10 5 
 
 
 
Consent Form 
You are requested to participate in a study conducted in the 
Department of Biochemistry, Chennai Medical College Hospital & 
Research Centre, Irungalur, Trichy, Tamilnadu titled “A study on 
Thyroid profile status in Type 2 Diabetes mellitus”. Your participation in 
the study is voluntary 
 There will be no cost for  participating in the study 
 Your participation is not a compulsion 
 You have the right to withdraw from the study at any time. 
 
Nature of Study: 
 If any abnormalities are identified, you will be informed for 
further consultation. 
 The results of this study will be kept confidential 
We believe that the results of this study will be beneficial for 
advancements in medicine & Science.  We assure you that we will not 
use these result for any other purpose. 
 
Consent 
I Mr /Mrs / Ms______________________________________________________________ 
residing at _____________________________________________________________________ 
____________________________________________________________on this day 
___________________  after having read the consent form carrying 
information for the above mentioned study and I hereby give my 
consent to take 4ml of my blood sample for the purpose of doing serum 
electrolytes. I was explained about the procedure in detail and give my 
consent for participating in the study and for using the results for 
Medical & Scientific purposes. 
 
 
Signature of the participant     Signature of Witness 
 
 
Signature of the Investigator   
 
 
Chennai Medical College Hospital & Research Centre 
Irungalur, Trichy – 621 105.  
